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                                                                                                                                  SUMMARY 
SUMMARY 
 
Oesophageal cancer (OC) is characterised by the development of malignant tumours in the 
epithelial cells lining the oesophagus. It demonstrates marked ethnic variation, with squamous 
cell carcinoma (SCC) being more prevalent in the Black population and adenocarcinoma 
(ADC) occurring more often in Caucasians. The aetiology of this complex disease has been 
attributed to a variety of factors, including an excess of iron (resulting in increased 
tumourigenesis), oesophageal injury and inflammation. 
The present study attempted to determine the mutation spectrum of the regulatory and coding 
regions of the ceruloplasmin (CP) gene, involved in iron metabolism, in the Black South 
African OC population. The patient cohort was comprised of 96 (48 male and 48 female) 
unrelated individuals presenting with SCC of the oesophagus. The control group consisted of 
88 unrelated, healthy population-matched control individuals. The techniques employed for 
mutation detection in this study included polymerase chain reaction (PCR) amplification, 
heteroduplex single-strand conformation polymorphism (HEX-SSCP) analysis, restriction 
fragment length polymorphism (RFLP) analysis followed by bidirectional semi-automated 
DNA sequencing analysis to verify the variants identified. 
Mutation detection of CP resulted in the identification of fourteen previously described 
(5’UTR-567C→G, 5’UTR-563T→C, 5’UTR-439C→T, 5’UTR-364delT, 5’UTR-354T→C, 
5’UTR-350C→T, 5’UTR-282A→G, V223, Y425, R367C, D544E, IVS4-14C→T, 
IVS7+9T→C and IVS15-12T→C) and four novel (5’UTR-308G→A, T83, V246A and G633) 
variants. Statistical analysis revealed that two of the novel variants were significantly 
associated with OC in this study; the promoter variant 5’UTR-308G→A (P=0.012) and the 
exonic variant G633 (P=0.0003). It is possible that these variants may contribute to OC 
susceptibility in the Black South African population. 
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                                                                                                                                  SUMMARY 
OC symptoms generally present late in the development of the disease, and as a result 
treatment after diagnosis is highly ineffective. Early detection of symptoms and subsequent 
treatment is therefore the most effective manner of disease intervention. In high incidence 
areas, such as the Transkei region of South Africa, the implementation of a screening 
programme would be the ideal way to achieve this goal. The information that can be gathered 
from the identification of potential modifier genes for OC can lead to improvements in early 
detection, which in turn may lead to advancements in the treatment and counselling to 
individuals with OC. To our knowledge, this is the first study concerning CP and its effects 
on iron dysregulation in the Black South African population with oesophageal cancer. 
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                                                                                                                              OPSOMMING 
OPSOMMING 
 
Oesofageale kanker word gekenmerk deur die ontwikkeling van kwaardaardige gewasse in 
die epiteelweefsel van die oesofageale voering. Hierdie siekte demonstreer opvallende etniese 
variasie, met plaveisel selkarsinoom meer algemeen in die Swart populasie en 
adenokarsinoom meer algemeen in die Kaukasiese populasie. Die ontwikkeling van hierdie 
komplekse siekte word aan ‘n aantal faktore toegeskryf, insluitend ‘n oormaat yster (wat lei 
tot ‘n vermeerdering van gewasse) en oesofageale besering en -ontsteking. 
Die doel van die hierdie studie was om die mutasie spektrum van die regulatoriese- en 
koderingsarea van die ceruloplasmin (CP) geen, betrokke in yster metabolisme, in die Swart 
Suid Afrikaanse oesofageale kanker populasie te bepaal. Die pasiënt groep het bestaan uit 96 
(48 manlik en 48 vroulik) onverwante individue met plaveisel selkarsinoom van die 
oesofagus. Die kontrole groep het uit 88 nie-geaffekteerde onverwante, populasie spesifieke 
individue bestaan. Die tegnieke aangewend vir mutasie deteksie in hierdie studie sluit in 
polimerase kettingsreaksie amplifikasie, heterodupleks enkelstring konformasie polimorfisme 
analise en restriksie fragment lengte polimorfisme analise, gevolg deur tweerigting semi-
geoutomatiseerde DNS volgorde-bepalingsanalise om die geïdentifiseerde variante te 
bevestig. 
Mutasie deteksie van CP het tot die identifikasie van veertien reeds beskryfde (5’UTR-
567C→G, 5’UTR-563T→C, 5’UTR-439C→T, 5’UTR-364delT, 5’UTR-354T→C, 5’UTR-
350C→T, 5’UTR-282A→G, V223, Y425, R367C, D544E, IVS4-14C→T, IVS7+9T→C en 
IVS15-12T→C) en vier nuwe (5’UTR-308G→A, T83, V246A en G633) variante gelei. 
Statistiese analise het getoon dat twee van die nuwe variante betekenisvol geassosieerd was 
met oesofageale kanker in hierdie studie; die promotor variant 5’UTR-308G→A (P=0.012) en 
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die eksoniese variant G633 (P=0.0003). Dit is moontlik dat hierdie variante mag bydra tot 
oesofageale kanker vatbaarheid in die Swart Suid Afrikaanse populasie. 
Oesofageale kanker simptome vertoon gewoonlik op ‘n latere stadium in die 
ontwikkelingsproses van die siekte, en as ‘n gevolg is behandeling na diagnose hoogs 
oneffektief. Vroegtydige identifikasie van die simptome en daaropvolgende behandeling is 
die mees effektiewe manier vir ingryping. In hoë voorkoms streke, soos die Transkei gebied 
van Suid Afrika, sal die implementasie van ‘n siftingsprogram die ideale manier wees om 
hierdie doel te bereik. Die inligting wat dan versamel word, insluitend identifisering van 
modifiserende gene vir oesofageale kanker, kan lei tot ‘n verbetering in vroegtydige deteksie 
van die siekte. In effek kan dit dan lei tot beter behandeling en berading vir individue met 
oesofageale kanker. So ver ons kennis strek, is hierdie die eerste studie wat CP en sy effek op 
yster disregulasie in die Swart Suid-Afrikaanse populasie met oesofageale kanker behels. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                             LITERATURE REVIEW 
1.1 OESOPHAGEAL CANCER 
 
1.1.1 Background 
 
Oesophageal cancer (OC) is the 15th most common cancer in developed countries of the 
world and the 4th most common in developing countries (Crespi et al. 1994). This disease 
typically arises from a malignancy of the epithelium lining the oesophagus. The oesophagus 
consists of three sections – the upper, middle and lower. The wall of the oesophagus is made 
up of layers of muscle and is lined by the epithelium (Yang and Davis 1988).  
OC characteristically originates in the lower layers of the cells lining the oesophagus, and 
grows steadily toward the outer layers of cells. The majority of tumours that develop in this 
region are malignant. These tumours are usually classified into two major subtypes, based on 
differences in tumour histology: adenocarcinoma (ADC) and squamous cell carcinoma 
(SCC). Occasionally small-cell carcinomas, that share many properties with small-cell lung 
cancer, may account for tumour malignancy in OC (Chen and Yang 2001).  
ADC is often associated with a history of gastro-intestinal reflux and Barrett’s oesophagus, 
and usually develops in the glandular tissue in the lower third of the oesophagus. It is 
characterised by replacement of the squamous epithelium in this region by columnar 
epithelium (Daly et al. 2000). In contrast, SCC develops in the squamous cells that line the 
upper portion of the oesophagus, and is relatively similar to head and neck cancers in its 
appearance (Yang and Davis 1988).  
Both histological subtypes of OC have different pathological and aetiological characteristics 
with ADC being more prevalent in Caucasians and SCC in African-Americans and Blacks 
(Lu 2000). OC is an extremely aggressive form of cancer and patients with the disease have a 
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poor prognosis. The disease is most often seen in persons over the age of 25, with mortality 
rates increasing steadily with age (Blot 1994). It is also more common in men, with males 
being two to four times more likely to develop OC than females.  
 
1.1.2 Diagnosis and development of OC 
 
Patients with OC present with a variety of symptoms, such as dysphagia (difficulty to 
swallow), loss of weight, nausea and vomiting, coughing and hematemasis (vomiting of 
blood). A substantial loss of weight is characteristic of poor nutrition resulting from the 
presence of the cancer, and can be an indicator of the patient’s prognosis (Fein et al. 1985). 
Tumour development can result in disruption of normal peristaltic events, which can lead to 
nausea, vomiting and regurgitation of food. Hematemasis is usually a result of the fragility of 
the tumour surface leading to bleeding (Ojala et al. 1982). 
 
The majority of patients with SCC only begin to develop the above symptoms when the 
tumour has grown to a size large enough to result in a noticeable obstruction of the 
oesophagus. Due to this fact, the age at which patients are first diagnosed tends to be more 
advanced than in other common cancers and means that the prognosis is extremely poor, 
usually less than six months (Enzinger and Mayer 2003). 
In contrast, ADC, which is the predominant cause of OC in the developed world, is generally 
caused by acid reflux from the stomach. These patients experience symptoms such as 
frequent heartburn and nausea. They tend to consult physicians earlier than patients with 
SCC, and as a result the disease is detected at an earlier stage and their prognosis is much 
improved. ADC is an extremely lethal form of OC, and although survival rates have 
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increased over the past few years, there is only about a 10% five year survival rate in most 
Western countries (Sundelöf et al. 2002). 
Diagnostic tests are available to patients presenting with the above-mentioned symptoms to 
determine if OC may be the cause. The most commonly used of these tests is a barium 
swallow or oesophagram, which uses a series of X-rays to examine the oesophagus. Barium 
is swallowed and coats the lining of the oesophagus so that it is clearly visible on an X-ray 
(Levine et al. 1997).  
Another common diagnostic test is oesophagoscopy (upper endoscopy). During this 
procedure, the inside of the oesophagus is examined using an endoscope. Any unusual 
growths are clearly noticeable as changes from the surrounding tissue. A tissue biopsy may 
also be performed at the same time (Kakushima and Fujishiro 2008). 
 
The development of most cancers, including OC, may be linked to the spread of the cancer 
cells to the surrounding lymph nodes and subsequently to other areas of the body (Siewert et 
al. 2001). OC is unusual with respect to other cancers as it spreads to the lymph nodes in an 
extremely erratic manner, making predictions about disease progression very difficult. OC is 
classified according to the 2002 American Joint Committee on Cancer tumour-node-
metastasis (TNM) classification system (Greene et al. 2002). This system classifies OC based 
on the characteristics of the primary tumour as well as tumour metastases. Different stages in 
the development of OC are widely recognized and utilized in determining the most effective 
treatment plan for the patient. These stages are as follows: stage 0, the cancer, also called 
non-invasive cancer or high grade dysplasia, has not spread to other parts of the body; stage I, 
the cancer occurs only in the top layer of cells lining the oesophagus; stage II, the cancer has 
invaded deeper layers of the oesophageal lining and may have spread to neighbouring lymph 
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nodes; stage III, the cancer has spread further into the wall of the oesophagus and to nearby 
tissues or lymph nodes; stage IV, the cancer has spread to other parts of the body.  
 
1.1.3 Demographics and aetiology of OC 
 
OC occurs in high frequencies around the world and is one of the leading causes of cancer-
related deaths worldwide. Incidence of OC shows marked geographic variation, occurring at 
high frequencies in so-called “oesophageal cancer belts”. These regions are separated into 
the Asian belt, which is made up of countries such as Iran, Iraq, China, Japan and Turkey. In 
the Caspian Sea region of Iran for example, cancers of the gastrointestinal (GI) tract 
(including OC) account for over half of all cancer related deaths (Mohebbi et al. 2008). 
Other areas of high incidence include France, South America and South and East Africa 
(Parkin et al. 2005). Oesphageal cancer is common in Africa, particularly in the Transkei 
region of South Africa, which is thought to be the centre of the disease in Africa (Sammon 
2007). An age-standardised incidence rate (ASIR) of 46.7 and 19.2/100,000 for males and 
females respectively was reported in this region (Makaula et al. 1996). 
SCC occurs at a higher frequency than ADC, with the highest incidence of ADC in North 
America and France. Whilst the incidence of SCC worldwide has remained relatively 
constant over the last few decades, cases of ADC have increased markedly. The reported 
increase in the white male population of the USA is reported to be close to 10%, which 
makes it the fastest growing form of cancer in that specific population (Pisani et al. 1999). 
Asian countries such as China (Zhang et al. 2004) and Singapore (Fernandes et al. 2006) 
have also shown an increase in incidence. 
As well as geographical differences between the two subtypes of OC, there has been found to 
be a difference in racial background. SCC is more prevalent in Blacks with ADC occurring 
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more often in Caucasians (defined as individuals from European descent). SCC is thought to 
be one of the leading causes of death among males of the Black population and the fourth 
most common cause of death among Coloured (defined as individuals of Mixed Ancestry) 
males in South Africa (Blot 1994). 
OC also shows variation in incidence in differing age groups with an increased risk with 
increasing age. The average age of diagnosis in South Africa is around 60 years of age 
(Pisani et al. 1999). 
 
1.1.4 Pathogenesis of OC 
 
1.1.4.1 Environmental risk factors 
 
The marked differences in the geographic and ethnic incidences of OC have been 
hypothesised to be due to variations in environmental factors in different populations 
originating from different regions (Marasas et al. 1988).  
 
(i) Diet and nutrition 
 
Particular diets from certain regions in the world may result in deficiencies of vitamins and 
micronutrients. Especially implicated are diets lacking vitamins such as B1 (riboflavin) and 
the mineral selenium. Individuals with lower levels of selenium have been shown to have an 
increased risk of developing OC (Wei et al. 2004, Cai et al. 2006). 
In a global study, low intakes of fruit and vegetables were found to account for 20% of all 
cases of OC and 19% of cases of gastric cancers worldwide (Lock et al. 2004). This is 
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thought to be due to the fact that the anti-oxidants, minerals and micronutrients present in 
fruits and vegetables, suppress the action of carcinogens and prevent oxidative DNA damage 
(Farrow et al. 2000). 
Areas of the Tanskei region of South Africa have diets based primarily on cereal grains, 
which are low in nutrients such as zinc and iron. As well as being relatively low in certain 
nutrients, food grains can also harbour fungal contamination. Fungal mycotoxins are a 
commonly known risk factor for the development of OC (Marasas et al. 1988). Fumonisin B1 
is a product of Fusarium moniliforme and is found on corn and maize throughout the world 
(Sammon and Iputo 2006). In Iran (Shephard et al. 2002), China (Yoshizawa et al. 1994) and 
Transkei (Marasas 1979) the mycotoxin was found at higher levels than in other areas with a 
lower incidence of OC. It has been hypothesized that the fungi themselves, as well as their 
mycotoxins, are mutagenic and directly affect DNA synthesis via sphingolipid metabolism in 
the cell (Abnet et al. 2001). A study by Lim et al. (1996) showed that the administration of 
high doses of fumonisin B1 in rats was able to stimulate the proliferation of oesophageal 
cells.  
Food infected with fungi may also contain N-nitrosamines, which have been shown to be 
carcinogenic to the oesophageal cells (Lijinsky et al. 1981). In combination with 
diethylnitrosamine, fumonisin B1 proved to be more toxic to oesophageal epithelial cells than 
alone (Myburg et al. 2002).  
In addition to a diet based on cereal grains, the population of Tanskei routinely supplements 
their diet with wild herbs and vegetables. Solanum nigrum (garden nightshade) is one of the 
commonly used plants, and has been shown to be used more often in areas with a higher 
incidence of OC (Rose 1982). A study of rats fed on S. nigrum resulted in an increase in the 
cells lining the oesophagus (Purchase et al. 1975), and a case-control study conducted by 
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Sammon (1992) in the Transkei demonstrated that the risk for developing OC was higher for 
individuals consuming S. nigrum than for individuals that smoked.  
Other potential dietary risk factors include high intake of dietary fat, cholesterol and animal 
protein, although these factors are not limited to OC alone (Mayne et al. 2001). 
 
(ii) Alcohol consumption and tobacco use 
 
The combined use of tobacco and alcohol has long been known to be associated with an 
increased risk of cancer development worldwide. OC is no exception, with the risk of disease 
development increasing with greater consumption of the tobacco product (Yu et al. 1988). In 
developed countries of the world with a high incidence of OC, alcohol and tobacco use 
(especially in combination) is the greatest risk factor (Day et al. 1994). The majority of areas 
in which OC is endemic, such as China, France and Italy, show a degree of association with 
tobacco use (Guo et al. 1994, Parkin et al. 1994). In South Africa a case control study by van 
Rensburg et al. (1985) showed a highly significant association (P = 0.0001) between cigarette 
smoking and OC. In the Black population of Soweto, South Africa, an increased risk for OC 
was observed for consumers of homegrown tobacco (either as hand-rolled cigarettes or 
chewing tobacco) when compared to cigarette smokers (Segal et al. 1988). In Transkei, 
tobacco cultivation, and its subsequent use, is lower in areas of low OC incidence and vice 
versa (Bradshaw and Schonland 1969). Other studies have demonstrated that 72% of OC 
patients in this region smoke (Sammon 1992) and 80% are consumers of traditional home-
brewed African beer (Segal et al. 1988). Alcohol use irritates the lining of the oesophagus, 
leading to inflammation that eventually may cause malignant changes in the cells. 
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(iii) Viral risk factors 
 
The human papilloma viruses (HPV) are a class of DNA viruses first shown to be implicated 
in the development of OC in a study conducted by Syrjanen (1982). To date, more than 70 
different types of the virus have been identified, and the association between HPV and OC 
confirmed by techniques such as polymerase chain reaction (PCR). 
In areas endemic for OC such as China and South Africa, the virus is frequently detected in 
patients with OC. In certain regions of China, 64% of OC patients were shown to have HPV 
DNA (Togawa et al. 1994). In South Africa, one study found evidence of HPV DNA in 10 
out of 14 OC patients studied (Williamson et al. 1991). In Transkei, 46% of OC patients were 
shown to be positive for HPV DNA from viral subtypes normally regarded as a low risk for 
OC pathogenesis (Matsha et al. 2002). 
In contrast, regions with a low incidence of OC (such as the USA and Northern parts of 
Europe) show relatively little HPV activity (Lam 2000). 
 
(iv) Gastro-oesophageal reflux and Barrett’s oesophagus 
 
Gastro-oesophageal reflux disease (GORD) is widely accepted as the risk factor most 
responsible for ADC. It is characterized by the movement of the stomach contents into the 
lower region of the oesophagus (Lagergren et al. 1999). Other factors influencing the 
development of GORD are ulcers in the oesophagus, hernias or difficulty in swallowing. 
Barrett’s oesophagus is a complication that arises due to long standing GORD (Goldblum 
2003) and results in replacement of the stratified squamous epithelium of the oesophagus and 
oesophagogastric junction with different types of columnar epithelium. This occurs as a result 
of inflammation (oesophagitis) of the lining of the oesophagus from the acidic stomach 
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contents. Paull et al. (1976) described three different types of epithelium that occur in 
patients with Barrett’s oesophagus: i) fundic-type, ii) cardiac-type (junctional) and iii) 
specialized columnar epithelium. Only the specialized columnar epithelium is susceptible to 
developing ADC (Chen and Yang 2001). 
 
(v) Obesity 
 
Obesity [body mass index (BMI) >30] is increasing at a rapid rate in western populations (11-
15% in men and 15-25% in women), and numerous studies have shown that this increase 
parallels the rise in OC (Seidell 1997, Chow et al. 1998). Increased intra-abdominal pressure 
in obese individuals may be a cause of gastro-oesophageal reflux, along with decreased 
emptying of the stomach contents and a lower oesophageal sphincter pressure.  
Chow et al. (1998) reported that having a BMI in the upper fourth of the scale compared with 
the lower fourth was associated with a dramatic increase in OC development. Lagergren et al. 
(1999) found similar results in a Swedish cohort. 
 
(vi) Other environmental factors associated with OC 
 
The consumption of hot beverages resulting in injury to the oesophagus accompanied by 
inflammation of the surrounding tissues has been implicated as a risk factor for OC (Yang 
and Wang 1993). 
Individuals exposed to the by-products of the mining and industrial sector in the workplace 
show an increased risk of SCC development. These substances include liquids (eg. benzene 
and xylene), dust (eg. carbon black) and aromatic hydrocarbons (Parent et al. 2000). 
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Exposure to asbestos, a known carcinogen, has been linked to the development of many types 
of gastrointestinal cancers including OC (Selikoff et al. 1979). This arises predominately due 
to chronic inflammation of the tissues lining the upper respiratory tract. 
 
1.1.4.2 Genetic risk factors 
 
As previously discussed, OC occurs predominately in two forms, SCC and ADC. It is 
common knowledge that the underlying causes of complex diseases such as cancer are related 
to both genetic and environmental factors. In both SCC and ADC the genetic risk factors 
involved are poorly defined and understood. However, recent studies have led to the 
discovery of various chromosomal abnormalities and gene alterations that may shed some 
light on changes at a genetic level that may contribute to the development of OC. 
 
Loss of heterozygosity (LOH) has proven to be an informative indicator of tumour-specific 
genetic alterations and is used in the analysis of human cancer cells as a method to define 
regions of the genome that may contain genes involved in tumour pathogenesis (Lasko et al. 
1991). The tumour-suppressor function of the retinoblastoma (Rb) gene on chromosome 
13q14 and the p53 tumour suppressor (p53) gene on chromosome 17p13 was elucidated 
using LOH as an approach (Huang et al. 1988, Chen et al. 1990). The most common genetic 
alterations occurring in OC that have been reported using LOH are allelic losses at 
chromosomes 3p, 5q, 9p, 13q, 17p, 7q, and 18q (Huang et al. 1992, Tarmin et al. 1994, 
Barrett et al. 1996, Shimada et al. 1996). 
 
Allelic loss on chromosome 17p occurs at a high frequency in many human cancers 
(Hollstein et al. 1996). This loss often includes the p53 locus which results in the inactivation 
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of the tumour suppressor function of this gene. With regard to OC, studies have shown 
increased frequencies of p53 mutation in one allele of tumours that have retained both 17p 
alleles (Huang et al. 1993, Maesawa et al. 1994). This has led to the belief that the aberrant 
p53 protein exerts a dominant negative effect which is sufficient to interfere with the function 
of the remaining wild-type allele.  
Alterations of genes involved in the regulation of cell proliferation are common in OC. These 
include amplifications of the epidermal growth factor (EGF) receptor gene (EGFR) (Slamon 
et al. 1987, Zhou et al. 1994) involved in growth signal reception, amplifications of c-myc 
(Lu et al. 1988) and overexpression of cyclin D1 (Wang et al. 1994, Adelaide et al. 1995) 
involved in cell-cycle control.  
 
To date, nonepidermolytic palmoplantar keratoderma, also referred to as tylosis, is the only 
recognised familial syndrome responsible for the predisposition of SCC to patients. Tylosis 
patients are at a 95% risk of developing SCC by the age of 70 (Ellis et al. 1994). This rare 
disorder is characterised by thickening of the oral mucosa as well as increased keratinisation 
of the palms of the hands and soles of the feet. It is caused by a genetic abnormality of 
chromosome 17q25 and is inherited in an autosomal dominant manner (Risk et al. 1994). It 
remains to be determined if this gene plays a role in the aetiology of sporadic OC. 
There have also been studies that have reported genetic susceptibility of Barrett’s oesophagus 
and GORD with ADC (Eng et al. 1993). 
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1.2 IRON AND OC 
 
1.2.1 Mechanisms of iron carcinogenesis 
 
Iron is an essential nutrient required for a variety of cellular functions. However, when 
present in an amount that exceeds the requirements of the body, iron can be highly toxic to 
cells and tissues and iron homeostasis must therefore be tightly regulated. In many cases, an 
excess of iron may initiate the process of carcinogenesis. The toxicity of iron is largely 
related to its ability to catalyze the formation of free radicals which attack and damage 
cellular components leading to cell death and tissue injury. The manner in which free radicals 
are formed is based on the chemistry of the Fenton and Haber-Weiss reactions. During these 
processes, catalysis of iron results in hydroxyl radicals (OH-) from superoxide (O2-) and 
hydrogen peroxide (H2O2), which are termed reactive oxygen species (ROS) (Papanikolaou 
and Pantopolous 2005). 
A surplus of iron may lead to an increase in the oxidative stress of the cell resulting in 
accelerated tissue damage as well as the oxidation of proteins, membrane lipids and nucleic 
acids. It has been demonstrated that the increased oxidative stress resulting from excess iron 
in the liver, pancreas and skin may lead to an elevated risk for carcinomas and sarcomas 
respectively (Weinberg 1999). Increased levels of iron are also required for the sustained 
proliferation of tumour cells. Hann et al. (1990) showed that supplementation with iron 
enhanced the growth of human hepatoma cells. Conditions of iron overload may also impair 
the cytotoxic activity of tumouricidal-activated macrophages against tumour cells by 
inhibiting their growth (Weiss et al. 1992). In normal circumstances, loss of iron from a 
target cell results in anti-tumour activity, which is reduced when there is excess iron present 
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(Huot et al. 1990). For this reason, iron can be said to have an indirect carcinogenic effect on 
cells.  
Conditions of iron deficiency can be just as pathogenic to bodily tissues and cellular 
components as those of iron overload. Anaemia is a condition frequently associated with 
malignancies although the underlying mechanism of pathogenesis is not yet fully understood. 
Erythrocytes often have a shortened survival rate in cancer patients which is one of the causes 
of cancer-related anaemia. Erythropoiesis is unable to compensate for this due to the 
weakened response of the bone marrow of cancer patients (Zucker et al. 1974).  
Characteristic changes in iron homeostasis are often observed in cancer patients. Some of 
these include elevated serum ferritin levels and decreased serum iron concentrations, which 
suggest a movement of iron toward the storage sites (Dorner et al. 1983). Raised levels of 
serum ferritin have been proven to correspond with tumour progression in head and neck 
cancers (Rosati et al. 2000). 
 
1.2.2 Iron as a risk factor for OC 
 
The role of iron as a potential risk factor for the development of OC was previously described 
in Black South African patients who had dietary iron overload, hypothesised to be as a result 
of drinking traditional beer brewed in non-galvanised steel drums (Bothwell et al. 1964, 
MacPhail et al. 1979, Isaacson et al. 1985). The involvement of iron in the development of 
other cancers such as liver cancer has also been previously studied and attributed to dietary 
iron overload (Mandishona et al. 1998). Studies have also shown that an increase in dietary 
iron plays a role in the development of OC in groups other than the Black South African 
population (Amer et al. 1990, Rogers et al. 1993). For example, a study conducted on a 
Danish population with primary haemochromatosis and iron overload demonstrated that these 
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patients were at an increased risk of developing certain cancers, including OC (Hsing et al. 
1995). The study subjects were followed from the date of haemochromatosis diagnosis until 
the first date of cancer diagnosis or date of death, and the association between primary 
haemochromatosis and cancer was subsequently quantified. 
Further studies using rat models showed that iron supplementation could be indicated as a 
risk factor for developing OC. The rats that were supplemented with iron had increased levels 
of inflammation, cell proliferation and ROS compared to the control animals. Increased 
tumour development, subsequent to the development of Barrett’s oesophagus, in the lower 
regions of the oesophagus of the iron-supplemented rats was also noted (Goldstein et al. 
1998, Chen et al. 1999, 2000).  
 
1.3 IRON HOMEOSTASIS 
 
1.3.1 Iron distribution and circulation 
 
Iron is a trace element required by virtually all living organisms and is utilised in a variety of 
cellular and metabolic processes (Aisen et al. 2001). These include oxygen transport by the 
haem moiety of haemoglobin, electron transport on the cytochromes of the respiratory chain 
and various other enzymes, a few of which are involved in DNA synthesis (Lieu et al. 2001). 
Within the adult human body, iron constitutes approximately 35 mg/kg of body weight in 
women and a slightly higher level of 45 mg/kg in men (Andrews 1999) and is one of the most 
abundant metals in the body. The vast majority of the total body iron, about 60 to 70%, is 
bound to the haemoglobin proteins of the erythrocytes which circulate in the blood stream. A 
further 10 to 15% of iron is present in other enzymes and the cytochromes, but in normal 
circumstances this level never exceeds 4 to 8 mg of iron. In the plasma approximately 1% of 
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iron is transported by forming a complex with transferrin, an 80 kDa protein that contains two 
iron binding sites (Emerit et al. 2001). Transferrin-bound iron (TBI) is utilised predominately 
by the bone marrow to produce the haemoglobin of the erythroid cells. The remainder of the 
total body iron, 20 to 30%, which is surplus to immediate cellular requirements, is stored in 
ferritin (Conrad et al. 1999). Due to the high demand for iron by the erythrocytes (20 mg per 
day) for erythropoiesis, the vast majority of iron comes from the destruction of old red blood 
cells by reticuloendothelial macrophages. This macrophage iron recycling results in the 
release of haem molecules from the haemoglobin into circulation (Bottomley et al. 1995). 
 
1.3.2 Dietary iron uptake 
 
The regulation of the stores of iron within the body takes place primarily through the 
absorptive process in the duodenum and jejunum of the small intestine. This intestinal 
absorption of dietary iron is important in maintaining the iron balance as the body has no 
physiologic pathway to regulate iron excretion. Iron loss takes place to a small extent (1 
mg/day in an adult human) by excretion of iron in the urine and bile, sweating and the 
recurrent loss of cells from the skin and gut. Due to the regular blood loss during 
menstruation and childbirth, women lose additional iron from the high concentrations 
contained in the haemoglobins (Andrews et al. 1999). The loss of bodily iron via these 
processes is kept in balance by the absorption of 1 to 2 mg of iron from the diet daily. The 
relationship between the excretion and the absorption of iron leads to the maintenance of a 
relatively constant amount of stored iron throughout life. 
As stated previously, the regulation of iron takes place predominately at the level of 
absorption in the intestine. Specifically, dietary iron is taken up across the brush border of the 
intestinal enterocytes and subsequently released across the basolateral membrane into the 
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circulation. Iron exists in two forms, the ferric (Fe3+) and the ferrous (Fe2+) forms. Due to the 
fact that ferric iron is rendered insoluble at a pH level greater than 3, and ferrous iron remains 
soluble at pH 7, the absorption of ferrous iron is more efficient than that of ferric iron. 
Inorganic iron ingested from the diet exists in the oxidised ferric (Fe3+) form and therefore 
has to be reduced to the ferrous (Fe2+) at the apical membrane of the enterocytes before 
absorption of iron in the intestine can occur (Conrad et al. 1999). 
 
1.3.2.1 Non-haem iron uptake 
 
The small intestine is the site where the absorption of all iron from the diet occurs. The cells 
located on the intestinal villus, the enterocytes, are highly specialized cells that control the 
absorption of dietary iron, as well as its transfer to the circulation. The brush border 
ferrireductase enzyme, cytochrome b reductase 1 (CYBRD1), also referred to as duodenal 
cytochrome b (DCYTB), mediates the reduction of the ferric iron to ferrous iron (McKie et 
al. 2001). The divalent cation transporter 1 (DCT1), also known as divalent metal transporter 
1 (DMT1) or natural resistance-associated macrophage protein 2 (NRAMP2), transports the 
ferrous iron across the apical membrane, and into the lumen, of the enterocytes (Fleming et 
al. 1997). NRAMP2 acts as a proton-coupled divalent cation transporter (Gunshin et al. 
1997), and the low pH of the gastric environment provides a proton-rich environment which 
facilitates this transport. 
The inorganic iron released from haem (refer to section 1.3.2.2) or imported via DMT1 into 
the cytosol of the enterocyte enters the labile iron pool. It may then be stored within the cell 
as ferritin, or transported across the basolateral membrane into the circulation. The solute 
carrier family 40 (iron-regulated transporter) member 1 protein (SLC40A1), also referred to 
as the solute carrier family 11 (proton-coupled divalent metal ion transporter) member 3 
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protein (SLC11A3), or ferroportin 1 (FPN1), or the iron-regulated transporter 1 (IREG1) or 
metal transporter 1 (MTP1), is responsible for mediating the transport of iron across this 
membrane (Donovan et al. 2000). SLC40A1 works in conjunction with the proteins 
ceruloplasmin (CP) and hephaestin (HEPH). CP and HEPH are homologous multicopper 
ferroxidase proteins responsible for the oxidation of ferrous iron to ferric iron. HEPH is a 
membrane-bound protein located on the basolateral membrane of the enterocytes and CP is 
located primarily in the plasma (Harris et al. 1998). These two proteins are thought to 
function as aids in iron transport by creating ion gradients that favour the export of iron from 
cells (McKie et al. 2000). CP in particular is hypothesised to aid with the binding of iron in 
the ferric state to its plasma transporter, transferrin (Harris et al. 1998). 
 
1.3.2.2 Haem iron uptake 
 
Iron from haemoglobin contained in food is more efficiently absorbed than inorganic iron 
(Majuri and Grasbeck 1987). For this reason, haem enters the enterocyte in a different 
pathway than that of inorganic iron (Conrad et al. 1999). In the intestinal lumen, haem is 
enzymatically cleaved from haemoglobin or myoglobin, and enters the enterocyte as a 
metalloporphyrin (reviewed by Anderson et al. 2005). A haem carrier protein-1 (HCP1) has 
been identified and is believed to bind to haem and transport it across the apical membrane of 
the enterocytes (Shayeghi et al. 2005). It is thought that the haem-HCP1 complex enters the 
cell via receptor-mediated endocytosis and progresses to the endoplasmic reticulum (ER) 
(Shayeghi et al. 2005). Haem oxygenase 1 (HMOX1), located on the surface of the ER, 
degrades the haem and releases inorganic iron, which is either stored as ferritin or enters the 
circulation across the basolateral membrane (refer to section 1.3.2.1). Recently, it has been 
demonstrated that HCP1 may have a more defined role as a folate transporter in intestinal 
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tissues (Qiu et al. 2006). However, HCP1 is expressed in many tissues other than the intestine 
and subsequently its role in haem transport cannot be disregarded. 
 
Figure 1.1 A schematic representation of dietary iron uptake by the enterocyte. 
 
 
Legend to Figure 1.1 
Dietary iron in the intestinal lumen is reduced by CYBRD1 from the ferric form (Fe3+) to the ferrous form 
(Fe2+). Fe2+ is transported across the apical membrane by DMT1. Haem is enzymatically cleaved from 
haemoglobin and transported into the enterocyte via HCP1. HMOX1 releases ferrous iron from haem. The 
intracellular iron is either stored as ferritin or transported out of the cell by SLC40A1, which is located on the 
basolateral membrane. HEPH (membrane-bound) and CP (in the plasma) facilitate the export of iron by 
oxidising iron from Fe2+ to Fe3+, which subsequently binds to transferrin. Abbreviations: CP, ceruloplasmin; 
CYBRD1, cytochrome b reductase 1; DMT1, divalent metal transporter-1; Fe3+, ferric iron; Fe2+, ferrous iron; 
HCP1, haem carrier protein-1; HEPH, hephaestin; HMOX1, haem oxygenase-1; SLC40A1, solute carrier family 
40 (iron-regulated transporter) member 1; TBI, transferrin-bound iron. Adapted from Trinder et al. 2002. 
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1.3.3 Cellular iron uptake 
 
Iron is transported in the plasma bound to serum transferrin, which has a high affinity for 
ferric iron. Once bound to transferrin, iron is no longer toxic, as it is unable to generate free 
radicals in this state (Hoefkens et al. 1996). Transferrin is a glycoprotein consisting of two 
globular domains, each of which has a high-affinity binding site for an iron molecule (Yang 
et al. 1984). Transferrin exists in a mixture of three different states, iron-free (apo-
transferrin), one iron molecule bound (monoferric transferrin) and two iron molecules bound 
(diferric transferrin).  
Two types of transferrin receptors (TFRs) have been identified and isolated, TFR1 and TFR2 
(Kawabata et al. 1999). These receptors are located on the surface of cells and bind with a 
high affinity to diferric transferrin in a manner that is dependent on pH. The majority of cells, 
except mature erythrocytes, express TFR1 (Davies et al. 1981). In contrast to this ubiquitous 
expression profile, TFR2 is predominately expressed by the hepatocytes of the liver where 
TFR1 expression is relatively low (Kawabata et al. 1999). At the normal physiological pH of 
the body, TFRs have a high affinity for binding to diferric serum transferrin. The complex of 
TFR and transferrin is internalised by the process of receptor-mediated endocytosis. Once 
inside the cell, the endosomal lumen acidifies to a pH of around 5.5 via an ATPase proton 
pump, and as a result the binding of iron to transferrin is weakened and the iron is released. 
The transferrin molecules bound to the TFRs return to the surface of the cell where the 
neutral pH of the blood facilitates the release of apo-transferrin into the circulation to be re-
used. Once the ferric iron has been released from transferrin, it is reduced to ferrous iron 
before it passes into the cytoplasm of the cell via DMT1 located on the endosomal membrane 
(Fleming et al. 1998). The iron that is now in the cytoplasm of the cell can be utilised by the 
cell or used for the synthesis of haem. 
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Figure 1.2 A schematic representation of cellular iron uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diferric transferrin 
TFR1
TFR2 
Endosome 
DMT1 
H+ 
ATPase
Fe2+ 
Apo-transferrin 
Fe3+ 
           Plasma         Plasma Membrane                Cell
Ferritin 
Cytoplasm 
Legend to Figure 1.2 
In the plasma, ferric iron is bound by apo-transferrin to form diferric transferrin. In most cells, diferric 
transferrin binds to TFR1 (or TFR2 in the hepatocytes of the liver) on the cell surface. This complex is 
internalised via receptor-mediated endocytosis. An ATPase proton pump decreases the pH of the endosome and 
iron is released from transferrin. Iron is then transported over the endosome membrane into the cytoplasm via 
DMT1. Apo-transferrin TFR complexes are recycled back to the cell surface for another cycle of iron uptake. 
Abbreviations: ATP, Adenosine Triphosphate; DMT1, divalent metal transporter 1; Fe3+, ferric iron; Fe2+, 
ferrous iron; H+, proton; pH, percentage hydrogen; TFR1, transferrin receptor 1; TFR2, transferrin receptor 2. 
Adapted from Lieu et al. 2001. 
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1.3.4 Iron storage 
 
Iron that is not utilised immediately by the body for metabolic processes is stored as a reserve 
in the event that the levels of free body iron become low. In healthy individuals, 
approximately 20 to 30% of the total body iron is stored. Free iron is extremely toxic and 
aggregates to form toxic precipitates. To prevent this, iron is stored as ferritins and 
haemosiderins in reticuloendothelial macrophages and hepatocyte cells of the liver (Sargent 
et al. 2005).  
 
1.3.4.1 Hepatic iron storage 
 
The hepatocyte cells of the liver are the main site of iron storage within the body. Iron gains 
entry to these cells bound to transferrin via the TFRs located on the cell surface. If the iron 
levels within the cell exceed the cellular needs, the surplus is stored as ferritin predominately 
with a small amount stored as haemosiderin (Trinder et al. 2002).  
Ferritin exists as two subunits consisting of heavy (H for heavy or heart) and light (L for light 
or liver) chains that can store up to 4500 molecules of ferric iron (Theil 1998). H-ferritin has 
the ferroxidase ability to oxidise Fe2+, the predominant form of iron in the cytoplasm, to Fe3+, 
the preferred iron form for storage. Ferritin synthesis is induced in the presence of free iron 
and repressed in conditions of iron deficiency (Zahringer et al. 1976, Ke et al. 1998).  
The mechanism by which iron is released from ferritin is poorly understood to date; although 
it has been hypothesised that ferritin is degraded by lysosomes or protoeosomes in order to 
provide iron for systemic requirements (Aisen et al. 2001). 
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Haemosiderins are poorly defined in comparison to ferritin. They are thought to be iron-
protein complexes that form an insoluble iron storage system, and are derived from the 
degradation of ferritin. In normal homeostatic conditions, haemosiderin can be detected in 
low amounts in the body tissues. However, during primary and secondary iron overload 
haemosiderin levels increase dramatically (Sargent et al. 2005). Haemosiderin has been 
shown to be less effective than ferritin at generating free radicals via the Haber-Weiss-Fenton 
reaction, which could suggest a reason for the increase in haemosiderin levels during iron 
overload (O’Connell et al. 1986). 
 
1.3.4.2 Reticuloendothelial iron storage 
 
There are two mechanisms by which reticuloendothelial (RE) macrophages acquire iron. The 
first is via the TFR-transferrin complex (Testa et al. 1991) on the cell surface and the second 
is through the process of phagocytosing old erythrocytes (Deiss 1983). Haem contained in the 
erythrocytes is cleaved enzymatically by haem oxygenase (HMOX1) whereby it is either 
released, with the aid of SLC40A1 as previously described, into the plasma to be bound to 
transferrin or it is stored as ferritin within the macrophages. 
 
1.3.5 Regulation of iron homeostasis 
 
As previously mentioned, the body has no fixed pathway to deal with the excretion of iron 
that exceeds the levels needed by the body. In order to prevent conditions such as iron 
overload or anaemia, complicated control pathways exist to monitor the amount of iron that is 
absorbed or stored within the body. For this reason the majority of the proteins mentioned in 
relation to iron metabolism are under extremely tight genetic control and are up- or down-
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regulated depending on the levels of iron within cells and the availability of iron to cells. 
These control mechanisms involve changes at the level of transcription, translation, as well as 
post-translational modifications at the cellular level. With regard to the organism as a whole, 
iron homeostasis is dependent on mechanisms that monitor iron stores, the rate of iron use by 
the erythrocytes (Finch 1994) and hypoxia (Trinder et al. 2002). 
In order to explain the regulation of iron, two models have been proposed by Pietrangelo 
(2004) which include the crypt-programming model and the hepcidin model. These two 
models and post-translational control of iron regulation will briefly be discussed. 
 
1.3.5.1 Crypt programming model 
 
Intestinal cells of the duodenum called crypt cells are precursor cells that migrate onto the 
intestinal villi and differentiate to become mature enterocytes. These precursor cells are 
believed to sense the iron requirements of the body and regulate the absorption of dietary iron 
by the absorptive villus enterocytes accordingly. 
This model proposes that the crypt cells absorb iron from the plasma so that their intracellular 
iron levels match that of the body iron stores. This means that they are able to regulate the 
intestinal absorption of iron from the gut lumen as they migrate up the villi and mature into 
absorptive cells on the brush border themselves (Oates et al. 2000).  
TFR1 and TFR2 proteins mediate the uptake of transferrin-bound iron (TBI) from the plasma, 
and are found on the basolateral membrane of crypt cells. The high iron protein (HFE) is a 
heterodimeric membrane protein with the ability to form associations with TFR1 and is 
highly expressed in the crypt cells (Parkkila et al. 1997). Experiments by Waheed et al. 
(1999) demonstrated that by binding to TFR1 and modifying its expression, HFE could 
change the iron sensory function of the precursor cell. Other experiments have shown that 
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wildtype HFE binds to TFR1 and lowers the binding of TBI therefore lowering the levels of 
iron uptake. This leads to a decrease in intracellular iron concentrations and ferritin levels and 
an increase in the number of transferrin receptors that are present on the cell surface (Feder et 
al. 1997, Waheed et al. 1997).  
The Hfe knockout mouse model used in a study by Trinder et al. in 2002 showed that TFR1-
mediated uptake of iron from the plasma is decreased by the mutant HFE. These results add 
support to the hypothesis of the crypt cell model by demonstrating that normal HFE is 
responsible for regulating the uptake of TBI from the plasma by inducing TFR1 expression, 
but are as of yet not conclusive evidence. 
 
1.3.5.2 The Hepcidin model 
 
Hepcidin is a peptide protein synthesized predominately by the hepatocyte cells of the liver, 
with expression levels being dependant on the stage of hepatocyte differentiation 
(Papanikolaou and Pantopoulos 2005). It has antimicrobial properties and is thought to play 
an important role in maintaining iron homeostasis, mainly as a regulator of iron stores, but it 
is also able to act as an erythroid regulator (Ganz 2003). 
A study by Nicolas et al. (2001) using upstream stimulatory factor 2 (USF2) knockout mice 
unexpectedly demonstrated that the mice progressively developed iron overload in the tissues 
of the liver and pancreas, whilst the RE macrophages showed no increase in iron levels. 
These symptoms appeared to mimic those of haemochromatosis patients. It was found during 
further analysis that a recombination event had removed both USF2 and HAMP genes, and 
that it was in fact the resulting deficiency of hepcidin that was responsible for the observed 
phenotype. In later studies by the same group, over-expression of hepcidin-1 in transgenic 
mice was shown to result in severe iron-deficiency anaemia (Nicolas et al. 2002). 
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Low levels of hepcidin trigger an increased absorption of iron from the intestine as well as 
the release of iron from macrophages. In contrast, an excess of hepcidin results in a decrease 
of dietary iron uptake and the retention of iron by macrophages (Andrews 2008). In response 
to hypoxia and anaemia the expression of hepcidin is decreased, irrespective of the level of 
body iron stores. Increases in hepcidin levels have also been noted in humans and mice with 
inflammation, which has resulted in the theory that hepcidin may be responsible for the 
anaemia of chronic disease (Nicolas et al. 2002). 
Hepcidin appears to regulate iron efflux from cells by binding to ferroportin and internalising 
it (Nemeth et al. 2004). Rising levels of hepcidin, as a result of iron overload or 
inflammation, lower the rate of export of iron from macrophages and enterocytes. In 
conditions such as haemochromatosis when hepcidin expression is decreased, ferroportin is 
able to function normally and iron is released from the intestinal cells and macrophages (Siah 
et al. 2006).  
 
1.3.5.3 Post-translational control 
 
Post-translational regulation involves iron regulatory proteins (IRPs) and iron responsive 
elements (IREs). IRP1 and IRP2 are responsible for the post-translational control of iron 
homeostasis by binding to IREs (Hentze and Kuhn 1996). IREs are located in the 5’ and 3’ 
untranslated regions (UTRs) of mRNA that encodes proteins involved the regulation of iron 
homeostasis (Andrews 2008). IRPs that bind to IREs in the 5’ UTRs of mRNA have been 
shown to block translation, and IRPs binding to IREs in the 3’ UTRs stabilise the mRNA and 
therefore increase translation (Ganz and Nemeth 2006). Proteins that are under the control of 
IREs include those involved in iron storage, iron export, iron uptake and haem synthesis. 
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The regulation of the binding of IRPs to IREs can be attributed to a number of factors. For 
example, in cases of iron overload, an iron sulphur cluster assembles in IRP1 inhibiting 
binding to IREs (Pantopoulos 2005). With regard to IRP2, proteosomes bind to a specific 
iron-dependant domain in the presence of iron and degrade it, therefore preventing any 
interaction with IREs. 
 
1.4 GENES INVOLVED IN IRON HOMEOSTASIS 
 
There have been several genes implicated in the homeostasis of iron in the body. The 
majority code for the proteins that play a role in the storage and transport of iron. A summary 
of the genes discussed in previous sections is illustrated in Table 1.1. below. 
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Table 1.1 Genes involved in iron metabolism. 
Gene Protein Chromosomal location Protein function 
CP Ceruloplasmin (CP) 3q21-24 Serum ferroxidase 
CYBRD1 Cytochrome b reductase 1 (CYBRD1) 2q31 Reduction of Fe3+ to Fe2+ in gut lumen 
DMT1 Divalent metal transporter 1 (DMT1) 12q13 Transports iron from gut lumen into enterocyte; from endosome to cytoplasm 
H-Ferritin (FTH) 11q13 Oxidation of Fe
2+ to Fe3+ to be stored in 
ferritin 
Ferritin 
L-Ferritin (FTL) 19q13.3 Sequesters iron in the nuclear core of the ferritin protein 
HAMP Hepcidin 19q13 Systemic iron regulation 
HCP1 Haem carrier protein 1 17q11.2 Transport of haem across apical membrane of enterocyte 
HEPH Hephaestin (HEPH) Xq11-12 Membrane-bound ferroxidase 
HFE High iron protein (HFE) 6p21 Binds to TFR, reducing affinity for transferrin therefore reducing iron uptake 
HJV Haemojuvelin (HJV) 1q21 Modulator of hepcidin expression 
HMOX1 Haem oxygenase 1 (HMOX1) 22q12 Oxidation of haem to Fe2+ 
IRP1 Iron regulatory protein 1 (IRP1) 9p13-22 Bind to IREs of mRNA to post-translationally control protein expression 
IRP2 Iron regulatory protein 2 (IRP2) 15q25.1 Bind to IREs of mRNA to post-translationally control protein expression 
SLC40A1 Solute carrier family 40 (iron regulated transporter) member 1 (SLC40A1) 2 
Transports iron at basolateral membrane 
of enterocyte 
TF Transferrin (Tf) 3q21 Iron transport protein in the plasma and extracellular fluid 
TFR1 Transferrin receptor 1 (TFR1) 3q29 Iron uptake molecule of transferrin-bound iron into cells 
TFR2 Transferrin receptor 2 (TFR2) 7q22 Exact function unknown. Homolog of TFR1 
Adapted from Brittenham et al. 2000. 
 
The association of the gene ceruloplasmin with OC has been investigated in this study and 
therefore only this gene (in relation to other iron genes) will be discussed in more detail. 
27 
 
                                                                                                             LITERATURE REVIEW 
1.4.1 Ceruloplasmin 
 
1.4.1.1 Identification and mapping 
 
Larsen (1977) demonstrated that ceruloplasmin (CP) and the transferrin (TF) gene were 
linked in cattle (LOD score of 11.3). Weitkamp (1983) found a peak LOD score of 3.5 for 
linkage of CP to TF in human families with a recombination frequency of about 10-15%. 
These findings were conclusive evidence that CP and TF were linked. Once TF was mapped 
to chromosome 3q21-25, a linkage group consisting of CP was mapped to the same region. 
This was achieved by Southern blot analysis of human-mouse somatic cell hybrids and in situ 
hybridisation (Naylor et al. 1985, Yang et al. 1986). In these studies, other sites of 
hybridisation on different chromosomal sites suggest that there may be CP-like DNA 
sequences in other areas of the human genome.  
 
1.4.1.2 Structure of CP gene and protein 
 
The CP gene consists of 19 exons and spans approximately 50 kb (Daimon et al. 1995). CP 
codes for the ferroxidase protein, ceruloplasmin (CP). CP is comprised of a single 
polypeptide chain of 1046 amino acids, with a molecular mass of 132 kDa (Takahashi et al. 
1984). CP is a blue alpha-2-glycoprotein that binds 90-95% of plasma copper and has 6 to 7 
copper ions per molecule. 
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1.4.1.3 Function 
 
In most organisms, ferroxidases are the proteins that are essential for maintaining iron 
homeostasis (Sargent et al. 2005). CP has been shown to participate in iron homeostasis in 
swine afflicted with anaemia, as the condition is reversed in these animals following injection 
with ceruloplasmin (Ragan et al. 1969). CP is located primarily in the plasma and is 
responsible for driving iron transport from stores in various tissues (Cherukuri et al. 2005).  
 
The CP enzyme is synthesized in the liver and it catalyzes the oxidation of ferrous iron (Fe2+) 
to ferric iron (Fe3+), thereby creating an ion gradient favouring iron export from the cells 
(Sargent et al. 2005). Transferrin (TF) is the main iron transport molecule in the plasma, but 
it can only carry iron in the ferric state, therefore CP acts as an aid in iron transport in the 
plasma. Enzymatic oxidation of ferrous iron by CP has been hypothesized as an important 
step in the formation of TF (Osaki et al. 1966), via the incorporation of iron into apo-
transferrin. CP can also facilitate iron release from macrophages. CP is highly expressed in 
cells of the liver, brain and other tissues. It is not expressed in cells of the small intestine and 
therefore does not play an important role in iron release from intestinal enterocytes. This has 
been demonstrated in patients with aceruloplasminemia, and in ceruloplasmin null mutant 
mice that develop iron accumulation mainly in the liver and pancreas, but show no signs of 
abnormal intestinal iron absorption (Harris et al. 1999). These findings demonstrate an 
important physiologic role for CP in determining the rate of iron efflux from the cells in 
which iron is stored.  
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1.4.1.4 Ceruloplasmin and disease 
 
(i) Wilson-Menkes disease and aceruloplasminaemia 
 
CP was originally thought to be the gene responsible for Wilson-Menkes disorder, a rare 
disease characterized by accumulation of copper in the tissues and defective loading of CP 
with copper ions (Danks 1989). Harris et al. (1995) investigated a number of potential Wilson 
disease patients, a few of whom later turned out not to have the disease, but did display the 
characteristic molecular degeneration and low levels of serum CP. They identified a patient 
with a 5 bp insertion in exon 7 of CP, which resulted in a frame-shift mutation and truncated 
open reading frame. The mutation was confirmed in the heterozygous state in the patient’s 
daughter, leading to the identification of aceruloplasminaemia.  
Aceruloplasminaemia is an autosomal recessive disorder characterized by progressive 
neurodegeneration of the retina and basal ganglia and diabetes mellitus. Due to mutations in 
CP, iron accumulates in the pancreas, liver and brain. Accumulation in the eye may lead to 
retinal degeneration. 
Wilson-Menkes disease, on the other hand, has subsequently been found to be caused by 
mutations in the ATP7B gene on chromosome 13, which is a putative copper-transporting P-
type ATPase (Ala et al. 2007). 
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(ii) Parkinson’s disease 
 
Parkinson’s disease (PD) is a neurological condition, characterized by the presence of Lewy 
bodies and regional areas of neurodegeneration. In the majority of PD patients, ferric iron is 
found to be accumulated in the brain (Sofic et al. 1988). The transferrin/iron ratio is also 
decreased in PD patients, which suggests that there is a problem with the movement of iron 
(Loeffler et al. 1995). It is still not clearly understood what causes the ultimate neuronal 
death in PD patients, although new evidence suggests that increased oxidative stress may play 
a role. Iron may contribute to this by increasing the formation of free radicals within cells of 
the central nervous system (CNS). 
CP is a highly effective antioxidant because of its ability to oxidise highly toxic ferrous iron 
to the nontoxic ferric form, which helps to prevent damage to proteins, lipids and DNA 
(Gutteridge 1992). CP is expressed by astrocyte cells of the brain and cerebellum (Patel et al. 
2000) in an alternatively spliced glycosylphosphatidylinositol (GPI)-anchored form, and not 
in the secreted form produced by the hepatocytes of the liver (Patel and David 1997). This 
GPI-anchored form is thought to play a role in iron homeostasis and antioxidant activity 
within the CNS. The importance of CP is illustrated in patients with aceruloplasminemia who 
have massive iron deposits in the brain and liver which lead to neurodegeneration and motor 
incoordination. In a study by Patel et al. (2002), it was shown that Cp knockout mice had an 
accumulation of iron as well as increased free radical injury to the CNS. Levels of CP have 
been reported to be reduced in the cortex of Alzheimer’s patients (Connor et al. 1993) and the 
ferroxidase activity of CP is reduced in the cerebrospinal fluid in PD (Boll et al. 1999). It is 
therefore a possibility that disruptions to CP, either at the gene or the protein level, may 
contribute towards the process of neurodegeneration by increasing the levels of ferrous iron 
and subsequently the production of damaging free radicals. 
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(iii) Cancer 
 
CP acts as an acute phase protein which is up-regulated in response to injury and 
inflammation. In this manner, it contributes in a major way to the antioxidant defence system 
of human plasma. It does so by a variety of mechanisms which include the inhibition of iron-
dependent lipid peroxidation and OH formation from H2O2 via its ferroxidase activity, 
scavenging H2O2 and O2- and the inhibition of copper-induced lipid peroxidation by its ability 
to bind copper ions (Mukhopadhyay et al. 1998).  
Various studies have demonstrated that levels of CP are raised in patients with cancer (Boz et 
al. 2005, Doustjalali et al. 2006). An example of this was demonstrated in a study by Pousset 
et al. (2001) using transgenic mice that developed hepatocellular carcinomas. These mice 
were found to have extremely elevated levels of serum CP which could not be attributed 
exclusively to inflammation when compared to other studies. The mechanism underlying this 
is poorly understood, although it is thought that an increase in CP levels may be explained by 
a protective response to an increase in circulating Fe2+ unbound to transferrin. It may also be 
an attempt by liver hepatocytes to control excessive tumour proliferation by reducing the free 
iron available to the tumour cells (Hann et al. 1992). 
 
To date no conclusive evidence exists that links CP to the development of specific cancers. 
However, from the evidence presented above, it is becoming increasingly clear that CP plays 
an important role in the pathogenesis of cancer, particularly in its action as a potent 
antioxidant in response to infection and inflammation. Disruptions to the CP gene and/or 
protein may therefore have important clinical consequences in the aetiology of this complex 
disease. Further studies to elucidate the relationship between CP and cancer are therefore 
warranted. 
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1.5 OBJECTIVES OF THIS STUDY 
 
In order to gain a greater understanding of the pathogenesis of oesophageal cancer, the 
identification of modifier genes responsible for OC susceptibility is of great importance. The 
information that can be gathered from the identification of these potential modifier genes can 
lead to improvements in early detection of OC, which in turn may lead to advancements in 
the treatment and counselling to individuals with OC. 
The aims and objectives of this study are as follows: 
1) The mutation analysis of the gene Ceruloplasmin (CP), involved in iron metabolism, 
in patients with Oesophageal Cancer (OC) by: 
• PCR amplification of the promoter and coding regions of this gene. 
• Heteroduplex single-strand conformation polymorphism (HEX-SSCP) 
analysis, restriction fragment length polymorphism (RFLP) analysis and semi-
automated DNA sequencing analysis of the amplified regions to identify any 
novel and/or previously described variants in this gene. 
 
2) Statistical analysis of the variants identified to determine statistically significant 
associations that may exist between specific variants, or groups of variants, and OC 
pathogenesis and/or susceptibility. 
 
3) To determine if the effects of these variants in this gene are associated with its role in 
iron metabolism and possibly disease expression by in silico analysis. 
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2.1 MATERIALS 
 
This project has gained ethical approval from the Research and Ethics/Biosafety Committee, 
Faculty of Health Sciences, University of Stellenbosch, with reference number N07/06/147. 
 
2.1.1 Study cohort 
 
The study cohort for this study included 184 (96 patients and 88 controls) individuals from 
the Black Xhosa-speaking population of South Africa. All individuals are of Central African 
descent and observe cultural traditions originating from Xhosa tribes of South Africa. 
Patient samples were recruited from collaborating clinicians, who were responsible for 
clinical assessment. Patients with OC present with symptoms such as dysphagia (difficulty to 
swallow), loss of weight, nausea and vomiting, coughing and hematemasis (vomiting of 
blood). These patients were referred to the Provincial Hospital, Port Elizabeth for a barium 
swallow followed by biopsies in the theatre to confirm the presence of squamous cell 
carcinoma (SCC) or adenocarcinoma (ADC) on the basis of the histology. All of the patients 
in this study presented with SCC. 
The control individuals in this study consist of 88 unrelated, healthy individuals from the 
same population. These individuals were interviewed for a potential family history of 
relevant diseases and early screening for OC was performed using a Nabeya capsule for brush 
biopsy. Recruitment of the control individuals took place at the Mbekweni and Mpeko 
Clinics, Transkei. 
A whole blood sample was obtained with written informed consent from all of the study 
participants. 
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2.1.2 Patient demographics 
 
The patient cohort used in this study consisted of 96 Black South African individuals from 
the Transkei region of South Africa. The patient cohort included 48 (50%) males and 48 
(50%) females, with a mean age of 59 years [standard deviation (SD) ± 13 years] and 66 
years [standard deviation (SD) ± 12 years] respectively (Table 2.1). Demographic 
information on alcohol consumption and the smoking status of the patients is summarised in 
Table 2.1. Smoking status was restricted to cigarette smoking (including shop-bought and 
home-grown cigarettes). Alcohol consumption was restricted to beer (including shop-bought 
and home-made beer). 
 
Table 2.1 Patient demographics. 
   
OC Patients Demographic 
Males (n=48) Females (n=48) 
Average Age 59±13 66±12 
   
Smoking   
Yes 9 (19%) 4 (8%) 
Stopped 27 (56%) 18 (36%) 
Never 4 (8%) 13 (27%) 
Unknown 8 (17%) 13 (37%) 
   
Alcohol consumption    
Yes 31 (65%) 25 (52%) 
Stopped 2 (4%) 0 
Never 6 (13%) 10 (21%) 
Unknown 9 (19%) 13 (27%) 
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2.1.3 Body iron status 
 
In the current study, the transferrin saturation (TS) and the serum ferritin (SF) levels were 
measured in the patient and control cohorts according to standard methodology. Iron overload 
parameters were defined as the percentage transferrin saturation (%TS) > 45 and/or serum 
ferritin exceeding 200 μg/l in females and 300 μg/l in males (Looker and Johnson 1988, 
Adams and Chakrabarti 1998). 
 
The iron status of each individual was classified into one of four groups (see Table 2.2): iron 
deficiency (SF < 20 μg/l), normal serum ferritin levels (females: SF between 20 and 200 μg/l 
and males: SF between 20 and 300 μg/l), raised serum ferritin levels (females: SF > 200 μg/l 
and males: SF > 300 μg/l) with %TS < 45 and raised serum ferritin levels with %TS > 45. 
 
Table 2.2 Iron status of the OC patients included in this study. 
     
  
Increased iron levels (Male: 
SF>300µg/l; Female: 
SF>200µg/l) 
  
Normal iron levels (Male: 
SF<300µg/l; Female: 
SF<200µg/l) 
Iron deficient 
(SF<20µg/l) 
%TS<45 %TS>45 
Male (n=48) 31 (64.5%) 0 17 (35.4%) 0 
Female (n=48) 25 (52.08%) 3 (6.25%) 19 (39.5%) 1 (2.08%) 
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2.2 DETAILED EXPERIMENTAL PROCEDURES 
 
Refer to Appendix 1 for a list of all chemicals/reagents and their respective suppliers used in 
this study. 
 
2.2.1 Total genomic DNA isolated from whole blood 
 
Total genomic DNA (gDNA) of the patient and control groups used in this study was 
available from a previous study (Human 2007). gDNA extractions were performed using 
whole blood samples collected in tubes containing ethylenediamine tetraacetic acid (EDTA) 
as the preservative, using a modified protocol of the salting out technique as described by 
Miller et al. (1988). 
 
2.2.2 Polymerase chain reaction (PCR) amplification 
 
2.2.2.1 Oligonucleotide primers 
 
The oligonucleotide primers used in this study were designed using the published CP 
reference sequence (Ensembl reference number ENSG00000047457 for the promoter region 
and GenBank reference number NM_000096 for the coding region) with the Primer3 v0.2 
program (Rozen and Skaletsky 2000). The reference sequence of the CP promoter and coding 
region, with the relevant positions of the primers designed, is illustrated in Appendix 2. The 
DNA samples were amplified using overlapping primers designed for the promoter region of 
the gene (Table 2.3) and intronic primers designed for the coding region of the gene (Table 
2.4)
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Table 2.3 Oligonucleotide primers used for PCR amplification of the CP gene promoter region. 
         
Primer Forward Primer Tm Reverse Primer Tm Product T1A T2A PCR 
Name (5'-3') (˚C) (5'-3') (˚C) Size (bp) (˚C) (˚C) Cycle 
CPP1a CCTGTTAGGCTCTGCTAGTT 60 CTTATGGGACCACCATCACA 60 267 56  A 
CPP2a AGAAATAGTCATGCACCAC 54 TGCATTGTTAGGCTATTTTG 54 311 60 55 B 
CPP3a CAGGTTTGTAGCCTAGGAGC 62 ATGCTCCCTTTGTTCCTCTG 60 282 56  A 
CPP4a CTCAGAACGTATCCCTGTCAT 62 TTGCCAGGCTTCTCTGACTG 62 275 57  A 
CPP5a CAGAGGAACAAAGGGAGCAT 60 GGAGCCTGAGAAGAAATGAAG 62 318 57  A 
CPP6a CAGTCAGAGAAGCCTGGC 58 GTGACTTACGTGTCAACAG 56 466 56  A 
         
Abbreviations: 5', 5-prime; 3', 3-prime; ºC, degrees Celsius; bp, base pair; CP, Ceruloplasmin gene; CPP1-6, Ceruloplasmin promoter fragments 1 to 6; PCR, polymerase 
chain reaction; T1A, annealing temperature 1; T2A, annealing temperature 2; Tm, melting temperature [Tm = 2(nA+nT)+4(nG+nC)]. References: aM Hallendorff (2008). 
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Table 2.4 Oligonucleotide primers used for PCR amplification of the CP gene coding region. 
         
Exon Primer Forward Primer Tm Reverse Primer Tm Product TA PCR 
 Name (5'-3') (˚C) (5'-3') (˚C) Size (bp) (˚C) Cycle 
1 CP1b AGGCTCCAAGAAGGGGAAA 58 CAAGCCCACATTTTGCAG 54 288 62 A 
2 CP2Ab TGGAGGCATCCCTACAACAG 62 TAGGGCCTAAAAACCCAAGC 60 280 62 A 
 CP2Bb GGCCCAGATAGAATTGGGAGA 64 AGCTAAAAGGCACTTCTATCG 60 281 60 A 
3 CP3Ab AACACATCCCCAAGGATCAC 60 CACAATTGCCATCTCCTTCC 60 257 61 A 
 CP3Bb CTTCCTAGGGGCCATCTACC 64 GCCCCTGTCTTTTGGTCATA 60 269 60 A 
4 CP4b CATGCTAAAAGTTTAGTCTTG 56 ATGTGAGGGAATAAGCTTAGC 60 297 61 A 
5 CP5Ab GAGGTAACTCTCACTATCTC 58 TTGTGTCAATACGGTAGTTC 56 224 61 A 
 CP5Bb CTCCCAGGACTCTCCATGGTG 68 CACCTTTTTCAGCTGACTGC 60 273 61 A 
6 CP6b ACCCGAGCAGTGTTTACAGG 62 GTGCGGGGGAGAGCATATT 60 300 60 A 
7 CP7b GTTCTACTTCAACCCCAGCA 60 CCCATGGGAAGAGTAAACCA 60 230 62 A 
8 CP8b GCATGTTACATACCAAGGAAGG 64 CCTGCCTTCAGTTTTTGCAG 60 290 60 A 
9 CP9b GGCTCAAATGACCACGTTAG 60 TTTTTCCCCAGTTGGACTTAC 60 291 61 A 
10 CP10b TGCACATGGAAGTCTTCTGC 60 GGTAGATTGGTGGATGATGC 60 242 60 A 
11 CP11Ab GGGCAAGCCTGAATAGGTCT 62 GCTGTGTCTCTCCATTCTCC 64 281 60 A 
 CP11Bb ATCAGCCGGGTCTCACTATG 62 GCTTGGGGAAGGGATAAGTT 60 294 60 A 
12 CP12b CAGAGGGCACTAGCAAAGAAG 64 TTGGGAATCAGAGTCTGGAG 60 283 60 A 
13 CP13b CATTAAGACAAAACTAACC 50 CCCACACCTGATAAACTGGAG 64 214 56 A 
14 CP14b CCATGGGGGAGAGAAACAAG 62 CAGCCTGTTAAAATGCACCA 58 270 61 A 
15 CP15b GTTCCTGGGTCCTAGTTATC 60 GGGAAGTGTCACAAAACAAATG 62 255 62 A 
16 CP16Ab CCTGGGTGCAAAGTCTCAGT 62 CTTTCTCGGGGTGATCAGAG 62 249 62 A 
 CP16Bb CAATCCCAGAAGGAAACTGG 60 CAAAGTGAGGCAGAAGTGGT 60 276 61 A 
17 CP17b ATCCTGAAAAGTAACATAAAACC 60 GCACCGGCTGTACTCTTTG 60 295 61 A 
18 CP18b TTCAATATCCCTGAGCTGAACA 62 TGGCTTCTAGAATTACTACCTGGA 68 283 61 A 
19 CP19b ATGAATCAGGAGTAAAGTAAC 56 TTCCCCCACAAATGTACAAAG 60 279 61 A 
         
Abbreviations: 5', 5-prime; 3', 3-prime; ºC, degrees Celsius; bp, base pair; CP, Ceruloplasmin gene; CP1-19, Ceruloplasmin coding fragments 1 to 19; PCR, polymerase 
chain reaction; T1A, annealing temperature 1; Tm, melting temperature [Tm = 2(nA+nT)+4(nG+nC)]. References: bThis study.  
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All primers were manufactured by Inqaba Biotechnical Industries (Pty) Ltd (Pretoria, South 
Africa) and Integrated DNA Technologies (IDT). The melting temperature (Tm) was 
calculated for each of the primers using the following equation as described by Thein and 
Wallace (1986): Tm = 2(nA + nT) + 4(nG + nC).  
 
2.2.2.2 PCR reaction and DNA amplification 
 
PCR conditions were optimized for each specific primer pair and are indicated in Tables 2.3 
and 2.4. PCR amplification of the promoter and coding region was performed in a 
GeneAmp® 2700 PCR System (Perkin Elmer Applied Biosystems, Warrington, WA, Great 
Britain) in reactions with a total volume of 25 µl, consisting of 0.5 U Taq polymerase enzyme 
(BIOTAQ™ DNA polymerase, Bioline Ltd., London, England), 50 ng DNA template, 0.2 
mM of each dNTP (dATP, dCTP, dTTP, dGTP) (Fermentas), 10 pmol of each primer, 1 × 
Buffer (Bioline) and 1.5 mM of magnesium chloride (MgCl2). For every round of PCR 
amplification performed, a negative control (reaction without gDNA template) was included 
to indicate the possibility of contamination in the PCR reactions. 
Two different PCR cycle programs, namely A and B, were utilised for the amplification of 
the gene (see Tables 2.3 and 2.4) and are described below: 
 
Cycle A 
 
An initial denaturation step at 95˚C for 5 minutes, followed by 35 cycles of denaturation at 
95˚C for 30 seconds, annealing at a temperature optimized for each primer set (indicated as 
the T1A of each amplicon in Table 2.3 and as the TA in Table 2.4) for 45 seconds and an 
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elongation step of 72˚C for 30 seconds. This was followed by a final extension step of 72˚C 
for 10 minutes. 
 
Cycle B 
 
An initial denaturation step at 95˚C for 5 minutes, followed by 10 cycles of denaturation at 
95˚C for 30 seconds, annealing at a temperature optimized for the primer set (indicated as the 
T1A of the amplicon in Table 2.3) for 45 seconds and an elongation step of 72˚C for 30 
seconds. This was then followed by 30 cycles of the same conditions but with an annealing 
temperature as specified in Table 2.3 as T2A, followed by a final extension step of 72˚C for 
10 minutes. 
 
2.2.3 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was used to test for successful amplification of the PCR 
products. Following PCR amplification, each sample was electrophoresed on a 2% (w/v) 
horizontal agarose gel [consisting of 4g agarose in 200 ml 1 × Tris-Borate-EDTA (TBE) (90 
mM Tris-HCl, 90 mM boric acid (H3BO3) and 0.1 mM EDTA, pH 8.0) and 0.01% (v/v) 
ethidium bromide (EtBr)]. 
The PCR product (5µl) was mixed with an equal volume of cresol red loading buffer [2 
mg/ml cresol red and 35% (w/v) sucrose] and loaded into the wells of the gel. The size of 
each specific fragment was compared against an appropriate molecular size marker [100 bp 
ladder (Generuler™, Fermentas)] loaded alongside the PCR samples. Resolution of the PCR 
products was performed at 120 V for 1 hour in 1 × TBE buffer solution. The DNA was 
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visualised by ultraviolet light transillumination and captured using the MultiGenius Bio 
Imaging System (Syngene, Cambridge, England). 
 
2.2.4 Heteroduplex single-strand conformation polymorphism (HEX-SSCP) analysis 
 
HEX-SSCP analysis (Kotze et al. 1995) was performed on a 16 cm vertical gel apparatus 
using the Hoefer SE 600 Basic slab gel apparatus. The PCR products of the promoter 
amplicons and the various exons were resolved on a 12% polyacrylamide (PAA) gel 
supplemented with urea [(NH2)2CO] [gel consisting of 7.5% (w/v) (NH2)2CO, 1.5 × TBE 
(135 mM Tris-HCl, 135 mM H3BO3 and 2 mM EDTA, pH 8.0), 12% (w/v) PAA [of a 40% 
stock solution with 1%C [99 acrylamide (AA): 1 bisacrylamide (BAA)], 0.1% (w/v) 
ammonium persulphate (APS) and 0.1% (v/v) TEMED]. 
A 0.75 mm gel was cast and allowed to polymerise. Gels were placed in a Hoefer SE 660 
electrophoresis tank filled with fresh 1 × TBE buffer. The upper buffer chamber was filled 
with 1.5 × TBE buffer. Prior to loading, 15 µl of bromophenol blue (C19H10Br4O5S) loading 
buffer [consisting of 95% formamide (H2NCHO) (v/v), 20 mM EDTA, 0.05% (w/v) xylene 
cyanol (C13H28N2Na4O13S ) and 0.05% (w/v) bromophenol blue] was added to 20 µl of each 
of the PCR products; heat denatured for ten minutes at 95ºC and then immediately cooled to 
4˚C by placing on ice. Approximately 15 μl of the denatured PCR product was loaded onto 
the gel using a Hamilton syringe. Electrophoresis was performed at 250 V (4ºC) for 18 hours. 
Following electrophoresis, visualisation of the DNA fragments on the PAA gels was 
achieved by placing them in an EtBr solution [0.01% (v/v)] for 10 minutes, followed by 3 
minutes of destaining in ddH2O. The DNA fragments were then subjected to ultraviolet light 
transillumination and photographed with the Multigenius Bio Imaging System (Syngene, 
Cambridge, UK). 
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2.2.5 Restriction fragment length polymorphism (RFLP) analysis 
 
In order to be able to distinguish clearly between the different genotypes of the T83 
polymorphism in exon 2 (amplicon 2A, see Table 2.4) of the CP gene, PCR products were 
subjected to RFLP analysis using the SfcI enzyme (recognition site: 5’ C↓TRYAG 3’; New 
England Biolabs Inc., Beverly, USA). This variant abolishes the SfcI restriction site, and 
therefore generates a single 280 bp product when present in the homozygous state following 
digestion. The wild-type homozygous state produces two fragments of 242 bp and 38 bp as 
the restriction site is uninterrupted in these samples, therefore allowing digestion to take 
place. The heterozygous state of the variant produces three fragments of 280 bp, 242 bp and 
38 bp. 
The PCR products together with the SfcI enzyme were digested overnight in 20 µl reactions 
consisting of 10 µl PCR product, 2 U of the enzyme and 1 × buffer, in a 37˚C water bath. 
Electrophoresis of the digested PCR products was performed on a 3% (w/v) horizontal 
agarose gel [consisting of 6g agarose in 200 ml 1 × TBE and 0.01% (v/v) EtBr]. The digested 
product (10 µl) was mixed with 5 µl cresol red loading buffer and loaded onto the gel. A 
molecular size marker [100 bp ladder (Generuler™, Fermentas)] was loaded alongside the 
samples in order to determine the correct size of the digested fragments. Resolution of the 
digested products was performed in 1 × TBE running buffer at room temperature at 80 V for 
the first hour, followed by 100 V for a further 2.5 hours. The DNA was visualised by UV 
light transillumination and captured as described in section 2.2.3.  
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2.2.6 Semi-automated DNA sequencing analysis 
 
2.2.6.1 DNA Purification 
 
Purification of the PCR products showing sequence variation upon HEX-SSCP analysis was 
performed using the Sigma GenElute™ PCR Clean-Up Kit (Sigma kit constituents not 
available). Briefly, a GenElute Miniprep Binding Column was placed within a collection tube 
and 500 μl of Column Preparation Solution was added. After a 1 minute centrifugation step at 
12000 × g (Centrifuge 5415D, Eppendorf), the eluate was discarded. A mixture of 500 μl 
Binding Solution and 100 μl PCR product was then transferred to the column and centrifuged 
at 15000 × g for the duration of 1 minute. The flow-through was discarded and 500 μl of 
Wash Solution added to the column, followed by further centrifugation at 15000 × g for 1 
minute. The flow-through was once again discarded followed by a further centrifugation step 
at 15000 × g for 2 minutes. The flow-through and collection tube were subsequently 
discarded and a new collection tube used with the column. After the addition of 10 μl sterile 
SABAX water to the column, it was centrifuged at 15000 × g for 1 minute and the 
subsequent eluate contained the purified PCR product. The DNA was stored at 4˚C. 
 
2.2.6.2 Cycle sequencing reaction and electrophoresis 
 
The cycle sequencing reaction consisted of a total volume of 7 µl, made up of 10 ng purified 
PCR product, 3.3 pmol primer and 1 µl of the BigDye® Terminator v3.1 Cycle Sequencing 
mix (Applied Biosystems, Warrington, WA, Great Britain). The same primers used for the 
PCR amplification were used (see Tables 2.3 and 2.4).The reaction was carried out using the 
GeneAmp® PCR System 2700 (Applied Biosystems). The following cycle sequencing 
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program was used: 25 cycles of denaturation at 96˚C for 10 seconds, annealing at 50˚C for 5 
seconds and an extension step at 60˚C for 4 minutes. Samples were subsequently sent to an 
analytical facility for post-cycle sequencing clean-up and electrophoresis of the sample on an 
ABI Prism 3130XL Genetic Analyser (Applied Biosystems). 
 
Analysis of the DNA sequences and chromatograms was performed by alignment with the 
published reference (wild-type) sequence (accession numbers listed in Section 2.2.2.1 and 
Appendix 2) using the BioEdit Sequence Alignment Editor v7.0.9.0 (Hall 1999), as well as 
visual inspection of the electropherograms to detect differences from the reference sequence. 
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2.3 STATISTICAL ANALYSIS 
 
The allele- and genotype frequencies of the variants detected were determined in both the 
patient and control groups by allele counting. The total carrier frequency, including 
heterozygotes and homozygotes, was counted to estimate gene variants. Statistical differences 
between the patient and control groups were tested for by chi-squared (χ2) analysis. 
Probability (P) values smaller than 0.05 (P < 0.05) were regarded as statistically significant. 
These analyses were conducted using Microsoft Office 2007 software and all results were 
verified using STATISTICA [StatSoft, Inc. (2003) STAT (data analysis software system), 
version 6]. Departure from Hardy-Weinberg equilibrium (HWE) in the patient and control 
groups was also tested for in the case of each variant that was identified. This was completed 
using a chi-squared (χ2) goodness-of-fit test using the Tools for population genetics 
association studies (TFPGA) program version 1.3 (Miller 1997). 
 
Haplotype analysis and linkage disequilibrium (LD) analysis was performed on each of the 
variants identified (Haploview 4.0, Barrett et al. 2005). Default parameters were applied to 
test for LD [the coefficient of association (D'): where D'=1 for perfect linkage disequilibrium; 
logarithm of the likelihood odds ratio, measure of confidence (LOD): LOD>3; correlation 
coefficient between two loci (r2): r2>0.8 where r2 =1 for prefect linkage disequilibrium]. The 
default block definition was applied (Gabriel et al. 2002) upon haplotype analysis. 
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2.4 BIOINFORMATIC ANALYSIS 
 
In silico analysis was performed on each of the variants identified in the promotor and coding 
regions in this study. Several bioinformatic databases are available for in silico analysis of the 
promotor region, of which the following two were used in this study: JASPAR CORE 
(Sandelin et al. 2004) and TRANSFAC®7 (Wingender et al. 2001). From TRANSFAC®7, 
two programs were used, namely PATCH and MATCH™ (v1.0) (Kel et al. 2005). The 
default parameters were employed in the use of both of these databases. In order to compare 
the putative transcription factor binding sites (TFBS) identified by these databases, the 
reference sequence (Ensembl, www.ensembl.org) was compared with the variant sequence. 
Using this analytical method, the creation or abolishment of a particular TFBS due to the 
particular nucleotide variation detected in this study could be determined.  
 
The ESEfinder (ESE-Exonic Splice Element) program was utilised for in silico analysis of 
the exonic variants identified in this study (Cartegni et al. 2003). ESEfinder was employed to 
determine the possible effect of the exonic variants on gene splicing. Putative ESEs in input 
sequences are searched for using weight matrices which correspond to the motifs of four 
different human serine/arginine-rich (SR) proteins.  
 
47 
 
  
 
 
 
CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
 
 
 
 
 
 
 
Presented in the form of a full-length manuscript in preparation for future publication in a 
scientific journal 
 
                                                                                                  RESULTS AND DISCUSSION 
 
Molecular Genetic Analysis of Ceruloplasmin in Oesophageal Cancer 
ABSTRACT 
 
OC is a disease characterised by the development of malignant tumours in the epithelial cells 
lining the oesophagus. It demonstrates marked ethnic variation, with SCC being more 
prevalent in the Black population and ADC occurring more often in Caucasians. The 
aetiology of this complex disease has been attributed to a variety of factors, including an 
excess of iron (resulting in increased tumourigenesis), oesophageal injury and inflammation 
(due in part to Barrett’s oesophagus and smoking among others). The aim of this study was to 
determine if genetic variations identified in the CP gene (implicated in iron homeostasis) 
contribute in any way to OC pathogenesis or susceptibility. The study cohort consisted of 96 
unrelated OC patients from the Black Xhosa-speaking South African population and 88 
population-matched control individuals. The promoter and coding regions of the CP gene 
were analysed for DNA sequence variation using heteroduplex single-strand conformation 
polymorphism (HEX-SSCP) analysis, restriction fragment length polymorphism (RFLP) 
analysis and semi-automated bidirectional DNA sequencing analysis. Fourteen previously 
described (5’UTR-567C→G, 5’UTR-563T→C, 5’UTR-439C→T, 5’UTR-364delT, 5’UTR-
354T→C, 5’UTR-350C→T, 5’UTR-282A→G, V223, Y425, R367C, D544E, IVS4-14C→T, 
IVS7+9T→C and IVS15-12T→C) and four novel (5’UTR-308G→A, T83, V246A and 
G633) variants were identified. Statistical analysis revealed that two of the novel variants 
were significantly associated with OC in this study and could, therefore, potentially 
contribute to disease susceptibility. This is the first study to examine CP with respect to OC 
in the Black South African population. As such, these findings should serve to further our 
understanding of the relationship between iron metabolism and disease pathogenesis. 
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INTRODUCTION 
 
OC is one of the leading causes of cancer-related deaths worldwide; it is the 15th most 
common cancer in developed nations and the 4th most common in developing countries such 
as South Africa (Crespi et al. 1994). The Transkei region of South Africa is thought to be the 
centre of the disease in Africa (Sammon 2007), with an age standardised incidence rate 
(ASIR) of 46.7/100 000 for males and 19.2/100 000 for females previously being reported 
(Makaula et al. 1996). OC shows clear geographic variation and occurs at a high incidence in 
certain areas of the world, which are termed “oesophageal cancer belts” (Blot 1994, Parkin et 
al. 2005). Two subtypes of OC exist, SCC and ADC, and both demonstrate marked racial 
variation which is characteristic of the disease. ADC is more prevalent in Caucasians and 
SCC occurs more frequently in Blacks. In South Africa, SCC is thought to be the leading 
cause of death among Black males and the 4th most common cause of death in Coloured 
males (Blot 1994). In addition, OC incidence rates also increase markedly with age, with the 
average age of disease diagnosis in South Africa being 60 years of age (Lagergren 2008). 
The combined use of tobacco and alcohol is one of the most important risk factors in the 
aetiology of OC in Western countries (Parkin 2001). Other risk factors include oesophageal 
injury and inflammation, infectious agents, nutrition, nitrosamines, mycotoxins and exposure 
to environmental toxins (Marasas 1979, Syrjanen 1982, Blot 1994, Parent et al. 2000, Matsha 
et al. 2002, Goldblum 2003). 
The relationship between iron and OC was previously described during a study of Black 
South African OC patients who were shown to have iron overload as a consequence of 
routinely drinking traditional beer brewed in non-galvanised steel drums (Bothwell et al. 
1964, MacPhail et al. 1979, Isaacson et al. 1985). It was demonstrated that excess dietary 
iron can act as a potential risk factor for the development of OC, and further studies have 
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shown that iron is involved in the development of other cancers such as liver cancer 
(Mandishona et al. 1998). In addition, studies using rat models showed that iron 
supplementation could be indicated as a risk factor for developing OC (Goldstein et al. 1998, 
Chen et al. 1999, 2000). Studies have also shown that an increase in dietary iron plays a role 
in the development of OC in groups other than the Black South African population (Amer et 
al. 1990, Rogers et al. 1993). It has also been demonstrated that loss of iron from a target cell 
results in anti-tumour activity, which is reduced when there is excess iron present (Huot et al. 
1990). For this reason, iron can be said to have an indirect carcinogenic effect on cells. 
Increased levels of iron can also inhibit the growth of tumouricidal-activated macrophages 
(Weiss et al. 1992). 
In order to further investigate iron as a risk factor for OC, this study focused on the analysis 
of the regulatory and coding regions of the CP gene, which is involved in iron homeostasis, 
in patients diagnosed with OC. CP is a ferroxidase enzyme synthesized in the liver which 
catalyses the oxidation of ferrous iron (Fe2+) to ferric iron (Fe3+), thereby creating an ion 
gradient favouring iron export from the cells (Sargent et al. 2005). Therefore, CP which is 
located primarily in the plasma is responsible for driving iron transport from stores in various 
tissues (Cherukuri et al. 2005).  
In this study, we aim to demonstrate the relationship between genes involved in iron 
metabolism (specifically CP) and the development of OC, by identifying gene variations that 
could potentially contribute toward iron dysregulation and subsequent disease pathogenesis. 
It is anticipated that the results obtained from this study will lead to a greater understanding 
of the role that iron homeostasis plays in the aetiology of OC. 
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MATERIALS AND METHODS 
 
The detailed experimental procedures employed in this study, as well as information 
regarding the study participants and ethical approval for this study, are described in detail in 
the Materials and Methods section (see Chapter 2). 
 
RESULTS 
 
3.1 MUTATION ANALYSIS 
 
The CP gene implicated in iron metabolism was screened in Black South African OC patients 
as well as population-matched control individuals. Mutation analysis of the entire CP gene 
revealed several variants (previously described and novel) following HEX-SSCP analysis. 
RFLP analysis was performed for specific variants where HEX-SSCP analysis proved 
inconclusive. All of the variants detected were verified by semi-automated bidirectional DNA 
sequencing analysis to confirm their presence. The positions of all the variants identified in 
this study are indicated on the CP reference sequence in Appendix 2. 
 
The PCR reaction for amplicon 13 (see Table 2.4) of the CP coding region could not be 
optimised and therefore mutation analysis for this region is incomplete. 
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3.1.1 Promoter variants 
 
Mutation analysis of the CP promoter region resulted in the detection of six previously 
described single nucleotide polymorphisms (5’UTR-567C→G, 5’UTR-563T→C, 5’UTR-
439C→T, 5’UTR-354T→C, 5’UTR-350C→T and 5’UTR-282A→G), one previously 
described single base pair deletion (5’UTR-364delT) and one novel single nucleotide 
substitution (5’UTR-308G→A). 
  
HEX-SSCP analysis of fragment 2 (see Table 2.3) of the promoter region revealed two 
previously described variants: 
The first was a C to G substitution (5’UTR-567C→G) (RefSNP ID: rs34053109) detected 
567 nucleotides upstream of the translation initiation site (ATG). This previously 
described variant was observed only in the heterozygous state and only in two of 86 
(2.3%) of the population-matched controls and none of the OC patients (Figure 3.1). 
 
The second previously described variant in fragment 2 of the CP promoter results from a T 
to C transition 563 nucleotides upstream of the initiating ATG (5’UTR-563T→C) 
(RefSNP ID: rs17838834). It was detected in the heterozygous state in 47 of 92 (51.1%) of 
the patients and in 38 of 86 (44.2%) of the controls. In the homozygous state, the variant 
was detected in seven of 92 (7.6%) of the patients and three of 86 (3.5%) of the controls 
(Figure 3.2). 
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Figure 3.1 Schematic representation of the 5’UTR-567C→G variant in the CP promoter. 
 
A. 
 
   C/G     C/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.1 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the 5’UTR-
567C→G variant in the heterozygous state. Arrow indicates the point of variation, green adenine or A, blue 
cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.2 Schematic representation of the 5’UTR-563T→C variant in the CP promoter. 
 
A. 
 
  T/T       C/C     T/C 
B. (i) 
 
B.(ii) 
 
B. (iii) 
 
Legend to Figure 3.2 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the 5’UTR-
563T→C variant in the heterozygous state (iii) the 5’UTR-563T→C variant in the homozygous state. Arrows 
indicate the point of variation, green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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HEX-SSCP analysis of fragment 3 (see Table 2.3) of the CP promoter revealed four 
previously identified variants: 
The first, a single base pair change at nucleotide position 5’UTR-439C→T was initially 
identified as a T to C transition. The common allele was initially identified upon 
inspection of a reference sequence (www.ensembl.org) and then cross referenced with 
another reference sequence from a different database (www.genatlas.org). However, in 
this study, it was found that the variant allele at position 5’UTR-439T→C had a higher 
incidence than the allele denoted on the reference sequence. After taking the ancestral 
allele from the HapMap project (The International HapMap Consortium, 2003) 
(http://www.hapmap.org) into consideration it was decided to annotate the variant using 
the common allele as the one with the higher frequency. This variant was subsequently 
annotated as 5’UTR-439C→T (RefSNP ID: rs701749). This variant was detected only in 
the heterozygous state, in one of 79 (1.3%) of the OC patients and three of 79 (3.8%) of 
the controls (Figure 3.3). 
 
The second previously described variant in fragment 3 was 5’UTR-364delT (RefSNP ID: 
rs17838833), which involves a deletion of the T nucleotide 364 nucleotides upstream of 
the translation initiation site. It was identified only in the heterozygous state and was 
limited to two of 85 (2.4%) of the patients (Figure 3.4). 
 
A previously described T to C substitution (5’UTR-354T→C) (RefSNP ID: rs17838832) 
was identified in the heterozygous state in 40 of 80 (50%) of the patients and 33 of 79 
(41.8%) of the controls. The homozygous state was detected in six of 80 (7.5%) of the 
patients and in six of 79 (7.6%) of the controls (Figure 3.5). 
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Figure 3.3 Schematic representation of the 5’UTR-439C→T variant in the CP promoter. 
 
A. 
 
   C/T       C/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.3 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the 5’UTR-
439C→T variant in the heterozygous state. Arrow indicates the point of variation, green adenine or A, blue 
cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.4 Schematic representation of the 5’UTR-364delT variant in the CP promoter. 
 
A. 
    T/-        T/T 
 
 
 
 
  
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.4 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band observed in the heteroduplex. B. Sequencing electropherograms indicating (i) the wild type 
sequence and (ii) the 5’UTR-364delT variant in the heterozygous state. Arrow indicates the point of variation, 
green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.5 Schematic representation of the 5’UTR-354T→C variant in the CP promoter. 
 
A. 
  C/C    T/C      T/T
 
B.(i) 
 
B.(ii) 
 
B.(iii) 
 
Legend to Figure 3.5 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the 5’UTR-
354T→C variant in the heterozygous state (iii) the 5’UTR-354T→C variant in the homozygous state. Arrows 
indicate the point of variation, green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Following HEX-SSCP analysis of promoter fragment 3, a fourth previously identified 
variant was observed. The 5’UTR-350C→T variant (RefSNP ID: rs34334174) results 
from a C to T substitution and was identified in this study in the heterozygous state in 16 
of 80 (20%) of the patients and 11 of 78 (14.1%) of the controls. In the homozygous state, 
this variant was detected in three of 80 (3.8%) of the patients and in only one of 78 (1.3%) 
of the control individuals (Figure 3.6). 
 
HEX-SSCP analysis of fragment 4 (see Table 2.3) revealed two variants, one novel and one 
previously described.  
 
The previously described variant was identified 282 nucleotides upstream of the ATG 
(5’UTR-282A→G) (RefSNP ID: rs17838831) and results from an A to G substitution. 
This variant presented in the heterozygous state in 20 of 53 (37.7%) of the patients and 20 
of 64 (31.3%) of the population-matched controls. In the homozygous state, it was 
detected in one of 53 (1.9%) of the patients and four of 64 (6.3%) of the controls (Figure 
3.7). 
 
The novel promoter variant occurs as a result of a G to A substitution 308 nucleotides 
upstream of the translation initiation site (5’UTR-308G→A). This novel polymorphism 
presented only in the heterozygous state and was not identified in the control individuals. 
It was detected in five of 52 (9.6%) of the OC patient individuals (Figure 3.8). 
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Figure 3.6 Schematic representation of the 5’UTR-350C→T variant in the CP promoter. 
 
A. 
 
   T/T        C/T          C/C 
B.(i) 
 
B.(ii) 
 
B.(iii) 
 
Legend to Figure 3.6 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the 5’UTR-
350C→T variant in the heterozygous state (iii) the 5’UTR-350C→T variant in the homozygous state. Arrows 
indicate the point of variation, green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.7 Schematic representation of the 5’UTR-282A→G variant in the CP promoter. 
 
A. 
 
    A/A         G/G          A/G 
B.(i) 
 
B.(ii) 
 
B.(iii) 
 
Legend to Figure 3.7 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band observed in the heteroduplex. B. Sequencing electropherograms indicating (i) the wild type 
sequence and (ii) the 5’UTR-282A→G variant in the heterozygous state (iii) the 5’UTR-282A→G variant in the 
homozygous state. Arrows indicate the point of variation, green adenine or A, blue cytosine or C, black guanine 
or G, red thymine or T. 
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Figure 3.8 Schematic representation of the novel 5’UTR-308G→A variant in the CP 
promoter. 
 
   A. 
 
 
    G/A      G/G 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.8 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the 5’UTR-308G→A variant in the heterozygous state. Arrow indicates the point of 
variation, green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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3.1.2 Exonic Variants 
 
Four previously described (V223, R367C, Y425 and D544E) and three novel (T83, V246A 
and G633) variants were identified in the coding regions of the CP gene following HEX-
SSCP analysis. The T83 variant was identified by RFLP analysis due to difficulties 
distinguishing between banding patterns on the HEX-SSCP gels. 
 
The first previously described exonic variant occurs at amino acid position 223 (V223) 
(RefSNP ID: rs35438054) and does not result in the replacement of the valine (V) amino 
acid. This synonymous variant was identified in exon 4 of the CP gene, and results from a G 
to C transversion at nucleotide position 661 (g.661 G→C). Following HEX-SSCP analysis, 
this variant presented only in the heterozygous state, in one of 95 (1.1%) of the patients and 
in one of 79 (1.3%) of the controls (Figure 3.9).  
 
A second previously described single nucleotide substitution was detected following HEX-
SSCP analysis of exon 6. This missense mutation is a C to T transition at nucleotide position 
1091 (g.1091 C→T) that results in the replacement of arginine (R) with cysteine (C) at amino 
acid position 367 (R367C) (RefSNP ID: rs34624984). The R367C variant was identified in 
the heterozygous state in three of 95 (3.2%) of the patient group and in one of 87 (1.1%) of 
the control group (Figure 3.10). The homozygous state was not observed. 
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Figure 3.9 Schematic representation of the V223 variant in the CP coding region. 
 
A. 
 
 
 G/C     G/G 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.9 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the V223 variant in the heterozygous state. Arrow indicates the point of variation, green 
adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.10 Schematic representation of the R367C variant in the CP coding region. 
 
A. 
 
 
  C/C     C/T 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.10 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the R367C variant in the heterozygous state. Arrow indicates the point of variation, green 
adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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HEX-SSCP analysis of exon 7 of the CP gene revealed a single previously described 
synonymous variant occurring from a T to C substitution at nucleotide position 1268 (g.1268 
T→C). This variant does not result in the replacement of tyrosine (T) at amino acid position 
425 (Y425) (RefSNP ID: rs34237139). Y425 was restricted to the heterozygous state and was 
detected in only one of 91 (1.1%) of the OC patients (Figure 3.11). 
 
HEX-SSCP analysis of exon 9 of the CP gene revealed the presence of a previously 
identified single base pair substitution, initially annotated as an A to T transversion, based 
upon the reference sequence employed. However, in this study, it was observed that the T 
allele occurred in a higher frequency than the A allele, and after considering the ancestral 
allele (HapMap) and international incidences of these alleles, it was decided to annotate the T 
allele as the common allele. Therefore the variant was annotated as a T to A substitution at 
nucleotide position 1625 (g.1625 T→A). This base pair substitution results in the 
replacement of aspartic acid (D) with glutamic acid (E) at amino acid position 544 (D544E) 
(RefSNP ID: rs701753). This missense mutation was observed in the heterozygous state in 42 
of 95 (44.2%) of the patients and 29 of 81 (35.8%) of the controls. The homozygous state was 
detected in one of 95 (1.1%) of the patients and seven of 81 (8.6%) of the controls (Figure 
3.12). 
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Figure 3.11 Schematic representation of the Y425 variant in the CP coding region. 
 
A. 
 
 
 
   T/T      T/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.11 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the Y425 variant in the heterozygous state. Arrow indicates the point of variation, green 
adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.12 Schematic representation of the D544E variant in the CP coding region. 
 
A. 
 
 T/T      T/A     A/A 
B.(i) 
 
B.(ii) 
 
B.(iii) 
 
Legend to Figure 3.12 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the D544E variant 
in the heterozygous state (iii) the D544E variant in the homozygous state. Arrows indicate the point of variation, 
green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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A novel synonymous variant was identified after mutation analysis of exon 2. This variant 
occurs from a T to C substitution at nucleotide position 249 (g.249 T→C), resulting in no 
change of the amino acid threonine (T) at position 83 (T83). Results from HEX-SSCP 
analysis of exon 2 were uninformative and the patient and control samples were therefore 
subjected to RFLP analysis for genotyping of this variant. The T83 variant abolishes a SfcI 
recognition site (5’ C↓TRYAG 3’). The homozygous wild type genotype results in two DNA 
fragments of 242bp and 38bp respectively, the heterozygous genotype results in three DNA 
fragments of 280bp, 242bp and 38bp, while the homozygous variant genotype results in a 
single DNA fragment of 280bp. The 38bp DNA fragment was not visible on a 3% (w/v) 
agarose gel but the 280bp and 242bp DNA fragments were able to be used for genotyping 
purposes. This novel variant was restricted to the heterozygous state and was identified in 
three of 92 (3.3%) of the patients and only one of 85 (1.2%) of the control individuals (Figure 
3.13). 
 
The second novel exonic variant identified in this study is caused by a T to C substitution that 
occurs at nucleotide position 729 (g.729 T→C) and results in the replacement of valine (V) 
with alanine (A) at amino acid position 246 (V246A). This missense variant was also 
identified in exon 4 of the CP gene following HEX-SSCP analysis and was restricted to both 
the heterozygous state and the patient group, where it was detected in two of 95 (2.1%) of the 
individuals (Figure 3.14). 
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Figure 3.13 Schematic representation of the novel T83 variant in the CP coding region. 
 
A. 
 
280bp 
242bp 
100bp
ladder
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.13 
A. 3% agarose gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
size of bands observed following RFLP analysis. B. Sequencing electropherograms indicating (i) the wild type 
sequence and (ii) the T83 variant in the heterozygous state. Arrow indicates the point of variation, green adenine 
or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.14 Schematic representation of the novel V246A variant in the CP coding region. 
 
A. 
 
 T/T       T/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.14 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the V246A 
variant in the heterozygous state. Arrow indicates the point of variation, green adenine or A, blue cytosine or C, 
black guanine or G, red thymine or T. 
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The final novel variant detected in the CP coding region was identified after HEX-SSCP 
analysis of exon 11. It occurs from a T to C transition at nucleotide position 1891 (g.1891 
T→C). This polymorphism does not result in the replacement of glycine (G) at amino acid 
position 633 (G633). The heterozygous state of this synonymous variant was observed in 13 
of 88 (14.8%) of the patient group (Figure 3.15). It was not detected in the homozygous state 
and was absent from the control group. 
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Figure 3.15 Schematic representation of the novel G633 variant in the CP coding region. 
 
A.     T/C             T/T 
 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.15 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the G633 variant 
in the heterozygous state. Arrow indicates the point of variation, green adenine or A, blue cytosine or C, black 
guanine or G, red thymine or T. 
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3.1.3 Intronic Variants 
 
Three previously described intronic variants (IVS4-14C→T, IVS7+9T→C and IVS15-
12T→C) were identified following HEX-SSCP analysis of the non-coding regions flanking 
the exonic regions screened in this study. 
 
The first intronic variant was observed after HEX-SSCP analysis of exon 5. The C to T 
substitution occurs 14 nucleotides upstream from the start of exon 5 (IVS4-14C→T) 
(RefSNP ID: rs34067682). It was observed exclusively in the heterozygous state and was 
identified in 37 of 95 (38.9%) of the patients and in 26 of 84 (31%) of the controls (Figure 
3.16). 
 
The second previously described non-coding variant was a T to C transition in intron 7, 
located 9 nucleotides downstream of the end of exon 7 (IVS7+9T→C) (RefSNP ID: 
rs35272481). This variant was detected in only one of 91 (1.1%) of the patients and only in 
the heterozygous state (Figure 3.17). 
 
The third intronic variant, a T to C substitution, was identified after HEX-SSCP analysis of 
exon 16. It is located in intron 15, 12 nucleotides upstream of the start of exon 16 (IVS15-
12T→C) (RefSNP ID: rs16861582). This variant was observed at high frequencies in both 
the patient and control groups. It was identified in 36 of 91 (39.6%) of the patients in the 
heterozygous state and in 44 of 88 (50%) of the controls. In the homozygous state it was 
found in 15 of 91 (16.5%) of the patients and in 15 of 88 (17%) of the control individuals 
(Figure 3.18). 
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Figure 3.16 Schematic representation of the IVS4-14C→T variant in the CP non-coding 
region. 
 
A. 
 
  C/T       C/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.16 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrow indicates 
aberrant band. B. Sequencing electropherograms indicating (i) the wild type sequence and (ii) the IVS4-14C→T 
variant in the heterozygous state. Arrow indicates the point of variation, green adenine or A, blue cytosine or C, 
black guanine or G, red thymine or T. 
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Figure 3.17 Schematic representation of the IVS7+9T→C variant in the CP non-coding 
region. 
 
A. 
 
 
   T/T      T/C 
B.(i) 
 
B.(ii) 
 
Legend to Figure 3.17 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the IVS7+9T→C variant in the heterozygous state. Arrow indicates the point of variation, 
green adenine or A, blue cytosine or C, black guanine or G, red thymine or T. 
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Figure 3.18 Schematic representation of the IVS15-12T→C variant in the CP non-coding 
region. 
A. 
 
 
  T/T     C/C    T/C 
B.(i) 
 
B.(ii) 
 
B.(iii) 
  
Legend to Figure 3.18 
A. HEX-SSCP gel stained with EtBr and visualised using ultraviolet light transillumination. Arrows indicate 
aberrant bands observed in the SSCP and heteroduplex. B. Sequencing electropherograms indicating (i) the wild 
type sequence and (ii) the IVS15-12T→C variant in the heterozygous state (iii) the IVS15-12T→C variant in 
the homozygous state. Arrows indicate the point of variation, green adenine or A, blue cytosine or C, black 
guanine or G, red thymine or T. 
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3.2 STATISTICAL ANALYSIS 
 
The variants identified in this study were subjected to statistical analysis. The polymorphic 
allele and genotype frequencies observed in the patients were compared to those of the 
population-matched control individuals and are shown in Tables 3.1 and 3.2. A Chi-squared 
(χ2) goodness-of-fit test using 2×2 (STATISTICA 8.0) or 2×3 contingency tables (Microsoft 
Excel Software), was employed to determine the probability (P) values for each identified 
variant in the patient and control groups (Tables 3.1 and 3.2). A P value of less than 0.05 
(P<0.05) was considered to be statistically significant (highlighted in yellow in Tables 3.1 
and 3.2).  
 
The patient and control groups were tested for deviation from Hardy-Weinberg Equilibrium 
(HWE) by utilising the χ2 goodness-of-fit test in the Tools for population genetics association 
studies (TFPGA) program v1.3 (Miller 1997). A probability value of greater than 0.05 
(P>0.05) was used to identify if a particular group conformed to HWE. The P values for the 
patient and control groups for each particular variant locus are shown in Tables 3.3 and 3.4. 
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Table 3.1 Genotypic and polymorphic allele frequencies of variants identified in the CP 
promoter region in the Black South African population. 
         
Variant Study cohort n Genotype  P 2n 
Variant 
Allelea P 
   CC CG GG   G  
5’UTR-567C→Gb,e Patients 84 1.00 0.00 0.00 168 0.00 
*rs34053109 Controls 85 0.98 0.02 0.00 
0.157 
170 0.01 
0.159 
   TT TC CC   C  
5’UTR-563T→Cc Patients 90 0.41 0.51 0.08 180 0.33 
*rs17838834 Controls 85 0.52 0.45 0.04 
0.229 
170 0.23 
0.127 
   CC CT TT   T  
5’UTR-439C→Tb Patients 79 0.99 0.01 0.00 158 0.01 
*rs701749 Controls 78 0.96 0.04 0.00 
0.305 
156 0.02 
0.308 
   TT T- --   -  
5’UTR-364delTb,d Patients 79 0.98 0.03 0.00 158 0.01 
*rs17838833 Controls 78 1.00 0.00 0.00 
0.157 
156 0.00 
0.159 
   TT TC CC   C  
5’UTR-354T→Cc Patients 80 0.43 0.50 0.08 160 0.33 
*rs17838832 Controls 78 0.50 0.42 0.08 
0.321 
156 0.30 
0.481 
   CC CT TT   T  
5’UTR-350C→Tc Patients 80 0.76 0.20 0.04 160 0.14 
*rs34334174 Controls 78 0.85 0.14 0.01 
0.284 
156 0.08 
0.125 
   GG GA AA   A  
5’UTR-308G→Ab,d Patients 52 0.90 0.10 0.00 104 0.05 
#This study Controls 64 1.00 0.00 0.00 
0.011 
128 0.00 
0.012 
   AA AG GG   G  
5’UTR-282A→Gc Patients 53 0.60 0.38 0.02 106 0.21 
*rs17838831 Controls 64 0.63 0.31 0.06 
0.539 
128 0.22 
0.835 
          
*RefSNP identification number; #This study; aAllele frequencies of only the polymorphic allele denoted; 
bvariants identified only in the heterozygous state; cvariants identified in both the heterozygous and homozygous 
states; dvariants identified in only the patient group; evariants identified only in the control group. Abbreviations: 
5’, 5 prime end; A, adenine; C, cytosine; del, deletion; G, guanine; n, number of individuals; 2n, number of 
alleles; P, probability value; T, thymine; UTR, untranslated region. 
 
 
 
 
 
79 
 
                                                                                                  RESULTS AND DISCUSSION 
 
 
Table 3.2 Genotypic and polymorphic allele frequencies of variants identified in the CP 
exonic and intronic regions in the Black South African population. 
           
Exon/ 
Intron Variant 
Study 
cohort n Genotype  P 2n 
Variant 
Allelea P 
2 T83b   TT TC CC   C  
 #This study Patients 92 0.97 0.03 0.00 184 0.02 
  Controls 84 0.99 0.01 0.00 
0.357 
168 0.01 
0.360 
4 V223b   GG GC CC   C  
 *rs35438054 Patients 95 0.99 0.01 0.00 190 0.01 
  Controls 85 0.99 0.01 0.00 
0.937 
170 0.01 
0.937 
4 V246Ab,d   TT TC CC   C  
 #This study Patients 95 0.98 0.02 0.00 190 0.01 
  Controls 85 1.00 0.00 0.00 
0.179 
170 0.00 
0.180 
4 IVS4-14C→Tb   CC CT TT   T  
 *rs34067682 Patients 84 0.69 0.31 0.00 168 0.12 
  Controls 83 0.69 0.31 0.00 
0.959 
166 0.12 
0.963 
6 R367Cb   CC CT TT   T  
 *rs34624984 Patients 94 0.97 0.03 0.00 188 0.02 
  Controls 86 0.99 0.01 0.00 
0.356 
172 0.01 
0.359 
7 Y425b,d   TT TC CC   C  
 *rs34237139 Patients 91 0.99 0.01 0.00 182 0.01 
  Controls 87 1.00 0.00 0.00 
0.327 
174 0.00 
0.328 
7 IVS7+9T→Cb,d   TT TC CC   C  
 *rs35272481 Patients 91 0.99 0.01 0.00 182 0.01 
  Controls 87 1.00 0.00 0.00 
0.327 
174 0.00 
0.328 
9 D544Ec   TT TA AA   A  
 *rs701753 Patients 95 0.55 0.44 0.01 190 0.23 
  Controls 81 0.56 0.36 0.09 
0.380 
162 0.27 
0.463 
11 G633b,d   TT TC CC   C  
 #This study Patients 88 0.85 0.15 0.00 176 0.07 
  Controls 84 1.00 0.00 0.00 
0.0003 
168 0.00 
0.0004 
15 IVS15-12T→Cc   TT TC CC   C  
 *rs16861582 Patients 93 0.28 0.56 0.16 186 0.44 
    Controls 88 0.33 0.51 0.16 
0.453 
176 0.41 
0.616 
           
*RefSNP identification number; #This study, aAllele frequencies of only the polymorphic allele denoted; 
bvariants identified only in the heterozygous state; cvariants identified in both the heterozygous and 
homozygous states, dvariants identified in only the patient group. Abbreviations: C, cytosine; IVS, intervening 
sequence; n, number of individuals; 2n, number of alleles; P, probability value; T, thymine. 
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Table 3.3 The Probability (P) values at variant loci in the CP gene promoter region were 
tested for departure from HWE. OC patients and control individuals from the Black South 
African population were analysed.  
   
Variant Study cohort P 
Patients - 
5’UTR-567C→G 
Controls 0.994 
Patients 0.363 
5’UTR-563T→C 
Controls 0.313 
Patients 0.998 
5’UTR-439C→T 
Controls 0.985 
Patients 0.994 
5’UTR-364delT 
Controls - 
Patients 0.459 
5’UTR-354T→C 
Controls 0.964 
Patients 0.374 
5’UTR-350C→T 
Controls 0.794 
Patients 0.936 
5’UTR-308G→A 
Controls - 
Patients 0.563 
5’UTR-282A→G 
Controls 0.791 
   
-, HWE not calculated as polymorphic allele not detected in respective group. Abbreviations: 5’, 5 prime 
end; A, adenosine; C, cytosine; del, deletion; G, guanine; P, Probability value; T, thymidine; UTR, 
untranslated region. 
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Table 3.4 The Probability (P) values at variant loci in the CP gene coding region were 
tested for departure from HWE. OC patients and control individuals from the Black South 
African population were analysed.  
    
Exon/Intron Variant Study cohort P 
Patients 0.987 
2 T83 
Controls 0.999 
Patients 0.999 
4 V223 
Controls 0.999 
Patients 0.995 
4 V246A 
Controls - 
Patients 0.245 
4 IVS4-14C→T 
Controls 0.239 
Patients 0.988 
6 R367C 
Controls 0.999 
Patients 0.999 
7 Y425 
Controls - 
Patients 0.999 
7 IVS7+9T→C 
Controls - 
Patients 0.062 
9 D544E 
Controls 0.762 
Patients 0.756 
11 G633 
Controls - 
Patients 0.433 
15 IVS15-12T→C 
Controls 0.882 
    
-, HWE not calculated as polymorphic allele not detected in respective group. Abbreviations: C, cytosine; 
del, deletion; P, Probability value; T, thymidine. 
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3.2.1 The HapMap project 
 
The HapMap project is in the process of developing a map of DNA sequence variation in the 
human genome that is available for public use. The HapMap study involves 270 individuals 
from three populations, European, Asian and African. The European population is 
represented by samples from the Centre d’Etude du Polymorphisme Humain (CEPH), the 
Asian population by unrelated Japanese and Han Chinese individuals and the African 
population by family groups from Nigeria. The aim of the project is to identify single 
nucleotide polymorphisms (SNPs) in these populations as well as the degree of association 
among them. Although not all populations are present in this study, the HapMap project is 
useful as a starting point when identifying variants in other populations. 
 
The polymorphic allele frequencies of the known variants identified in the South African 
Black control group (unaffected individuals) were compared to the allele frequencies for Sub-
Saharan Africans available on HapMap (Tables 3.5 and 3.6). Although the Black South 
Africans screened in this study do not display complete genetic similarity to the Sub-Saharan 
Africans on HapMap, the comparison of the allele frequencies does provide a minimum 
validation of the accuracy of the results obtained. The allele frequencies for the variants 
identified in the Black South African OC patients have also been included for reference in 
Tables 3.5 and 3.6, but should not be compared to the HapMap data as the allele frequencies 
available on this database refer to the general population and not a select group of individuals 
with a particular disease. HapMap European allele frequencies have also been provided. 
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Table 3.5 HapMap allele frequencies for known variants identified in the promoter region 
of the CP gene in this study. 
      
Polymorphic Allele Frequencies 
Variant  SA 
Black 
Patients 
SA Black 
Unaffected 
Individuals 
HapMap 
Unaffected 
Individuals 
HapMap Population 
Group 
0.02 SS African 
5'UTR-567C→G  0.00 0.01 
0.00 European 
0.07 SS African 
5'UTR-563T→C  0.33 0.23 
0.07 European 
0.00 SS African 
5'UTR-439C→T  0.01 0.02 
0.11 European 
0.03 SS African 
5'UTR-364delT  0.01 0.00 
0.09 European 
0.05 SS African 
5'UTR-354T→C  0.33 0.30 
0.07 European 
0.03 SS African 
5'UTR-350C→T  0.14 0.08 
0.00 European 
0.13 SS African 
5'UTR-282A→G  0.21 0.22 
0.18 European 
      
Abbreviations: 5', 5 prime end; A, adenine; C, cytosine; del, deletion; G, guanine; SA, South African; SS 
African, Sub-Saharan African; T, thymine; UTR, untranslated region.  
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Table 3.6 HapMap allele frequencies for known variants identified in the coding regions 
of the CP gene in this study. 
       
Polymorphic Allele Frequencies 
Exon/Intron Variant  SA 
Black 
Patients 
SA Black 
Unaffected 
Individuals 
HapMap 
Unaffected 
Individuals 
HapMap 
Population Group 
0.08 SS African 
4 V223  0.01 0.01 
0.00 European 
0.06 SS African 
4 IVS4-14C→T  0.12 0.12 
0.07 European 
0.02 SS African 
6 R367C  0.02 0.01 
0.00 European 
0.04 SS African 
7 Y425  0.01 0.00 
0.00 European 
0.04 SS African 
7 IVS7+9T→C  0.01 0.00 
0.00 European 
0.63 SS African 
9 D544E  0.23 0.27 
0.93 European 
0.58 SS African 
15 IVS15-12T→C  0.44 0.41 
0.21-0.32 European 
       
Abbreviations: C, cytosine; del, deletion; IVS, intervening sequence; SA, South African; SS African, Sub-
Saharan African; T, thymine.  
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3.2.2 Haplotype analysis 
 
LD and haplotype analysis, using the Haploview 4.0 software, was performed on all of the 
variants identified in this study using association and case-control studies (Barrett et al. 
2005). The LD test was applied, and a haplotype block consisting of the variant alleles of the 
promoter variants 5’UTR-563T→C, 5’UTR-439C→T, 5’UTR-354T→C, 5’UTR-350C→T, 
5’UTR-308G→A and 5’UTR-282A→G was predicted (D’=0.947, LOD=30.81, r2=0.875) 
(Figure 3.19). This haplotype spans a genomic region of 281 bp. Haplotype association 
frequencies demonstrated that this haplotype is significantly associated (P=0.01) with OC in 
the Black South African population.  
No other haplotypes were predicted to exist with any of the other variants identified in this 
study. 
 
Figure 3.19 LD plot of the statistically significant haplotype predicted using Haploview 4.0. 
 
Abbreviations: 5’, 5 prime end; A, Adenine; C, Cytosine; G, Guanine; T, Thymine; UTR, Untranslated region. 
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3.3 BIOINFORMATIC ANALYSIS  
 
3.3.1 In Silico analysis of promoter variants 
 
All the variants identified in the 5’UTR region of the CP gene were subjected to in silico 
analysis in order to determine if they disrupted or created any putative transcription factor 
binding sites (TFBS) predicted to occur within this regulatory region. This was achieved by 
comparing the published CP promoter reference sequence (see Appendix 2) with the variant 
sequence using the appropriate computer software. Identification of the same TFBS by more 
than one of the programs utilised increases the likelihood that the motif exists. The 
TRANSFAC®7 database (Wingender et al. 2001) was used for analysis of the promoter 
region in this study. Within this database, the PATCH and MATCH™ programs were 
employed to analyse the identified promoter variants. These variants were also analysed 
using the non-redundant JASPAR CORE database (Sandelin et al. 2004). For both of these 
two software programs, the default settings and parameters were employed to determine 
putative TFBS. 
 
The results obtained through in silico analysis of the promoter variants identified in the CP 
gene are shown in Table 3.7. 
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Table 3.7 Predicted TFBS in the promoter region of the CP gene. 
       
Putative Transcription Factor Binding Sites 
PATCH MATCH™ JASPAR CORE Variant 
Abolished Created Abolished Created Abolished Created 
5'UTR-567C→G YY1 GATA1 - HNF-1 FOXL1, YY1 GATA3 
5'UTR-563T→C 
YY1, HiNF-D, HiNF-
M, HiNF-P, TFIID, 
TMF, SRF 
RXRα, RXRγ, T3Rα - - FOXL1 FOXC1, SP1 
5'UTR-439C→T - - - AP-1 SPI1 SRY, NKX3-1 
5'UTR-364delT FOXM1a, FOXM1b, HNF-3α, HNF-3β GR HNF-3β - SRY, FOXD1 - 
5'UTR-354T→C SP1 c-myc - - - - 
5'UTR-350C→T GR, SPI1, NF-Y - - GR, C/EBPα - - 
5'UTR-308G→A p53 GR - - MAX, USF1, SPI1 FOXL1, 
5'UTR-282A→G  C/EBPα, HNF-1, HNF-3α  - C/EBPα - HLF, FOXL1, SRY, SOX9 GATA2, GATA3, SPIB 
       
Abbreviations: 5', 5 prime end; AP-1, Activator protein 1; C/EBPα, CCAAT/enhancer binding protein alpha; c-myc, Myelocytomatosis viral oncogene c; FOXC1, Forkhead 
box protein C1; FOXD1, Forkhead box protein D1; FOXL1, Forkhead box protein L1; FOXM1a, Forkhead box M1a; FOXM1b, Forkhead box M1b; GATA1, GATA-
binding protein 1; GATA2, GATA-binding protein 2; GATA3, GATA-binding protein 3; GR, Glucocorticoid receptor; HiNF-D, Histone nuclear factor D; HiNF-M, Histone 
nuclear factor M; HiNF-P, Histone nuclear factor P; HLF, Hepatic leukaemia factor; HNF-1, Hepatocyte nuclear factor 1; HNF-3α, Hepatocyte nuclear factor alpha; HNF-
3β, Hepatocyte nuclear factor 3 beta; MAX, Myc-associated factor X; NF-Y, Nuclear transcription factor Y; NKX3-1, NK 3 homeobox 1; p53, Tumour suppressor protein 
53; RXRα, Retinoid X receptor alpha; RXRγ, Retinoid X receptor gamma; SOX9, SRY (sex determining region Y)-box-9; SP1, Specificity protein 1; SPI1, spleen focus 
forming virus (SFFV) proviral integration oncogene 1; SPIB, SPI-B transcription factor; SRF, Serum response factor; SRY, Sex-determining region Y; T3Rα, Thyroid 
hormone receptor alpha; TFIID, Transcription factor IID; TMF, TATA element modulatory factor; USF1, Upstream transcription factor 1; UTR, untranslated region; YY1, 
Ying Yang 1. 
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3.3.2 In Silico analysis of exonic variants 
 
The exonic variants identified in this study included three novel (T83, V246A and G633) and 
four previously described (V233, Y425, R367C and D544E) variants. The ESEfinder (ESE-
Exonic Splice Element) program was used to analyse these variants identified in the coding 
regions of the CP gene to determine their possible effect on splicing (Cartegni et al. 2003). 
Results are tabulated in Table 3.8. 
 
Table 3.8 Predicted SR protein binding sites in the coding region of the CP gene. 
      
SR PROTEINS Variant 
SF2/ASF2 SF2/ASF2 (BRCA1) SRp40 SRp55 SC35 
T83     - 
V223 +     
V246A + +    
R367C   +  - 
Y425   -  + 
D544E     - 
G633         + 
      
-, SR protein binding site abolished; +, SR protein binding site created. Abbreviations: SR, serine/arginine-rich 
proteins. 
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DISCUSSION 
 
This study employed the techniques of HEX-SSCP analysis, RFLP analysis and semi-
automated DNA sequencing analysis to identify variations in the DNA sequence of the CP 
gene. Fourteen previously described and four novel variants were identified, with the 
majority proven to be single nucleotide polymorphisms (SNPs). 
 
SNPs are defined as DNA sequence variations that occur when a single nucleotide is altered. 
In order to be classified as a SNP, the least commonly occurring allele must be present in at 
least 1% of the general population. They occur at a frequency of approximately 1 in every 
1000 bp (Cooper et al. 1985) and are responsible for the majority of the genetic variation 
discernible between two individuals (Taillon-Miller et al. 1998). Identification of SNPs is one 
of the most common methods employed in the study of genetic variation and they are 
frequently used as markers to identify genes associated with conferring susceptibility to 
genetic disease. SNPs themselves are not always considered to be disease-causing. However, 
they may indicate a risk for the development of a certain genetic disease and are therefore 
invaluable in the study of genetic disease (Kruglyak 1999). 
 
Promoter region 
 
The cellular environment is in a constant state of flux. Genes have the capability to react to 
these changes via regulation of transcription. Transcription factors (TFs) and other cellular 
proteins bind to regulatory promoter elements in the genes and subsequently affect the rate of 
transcription (Butler and Kadonaga 2002). The regulatory elements to which TFs bind are 
termed transcription factor binding sites (TFBSs). 
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TFBSs are cis-acting elements that are generally comprised of a 6-25 bp recognition 
sequence and are highly conserved in eukaryotes (Lettice et al. 2002, Cooper and Sidow 
2003). The distribution frequency of TFBSs is not the same throughout the promoter regions 
of genes; the frequency appears to increase in regions close to the transcription initiation site 
(Guo and Jamison 2005). TFBSs are termed as enhancers if the binding of the relevant TF to 
the regulatory region results in activation of transcription. Conversely, TFBSs are termed as 
silencers if TF binding results in repression of transcription (Wang and Giaever 1988). It is 
important to note that although many genes may share identical sequences for a particular 
TFBS, the importance of each site differs with tissue type and the physiological environment. 
This, therefore, means that the presence of a particular TFBS in the regulatory region of a 
gene does not guarantee that the corresponding TF will bind in vivo (Li and Johnston 2001).  
 
A large variety of TFs are known to exist within eukaryotic cells. To date, more than 1400 
TFs have been described (Lander et al. 2001). SNPs that alter the expression of genes have 
been identified in the promoter regions of genes and are responsible for affecting the rate of 
transcription (Buckland 2004). These SNPs are termed regulatory SNPs (rSNPs) and they are 
usually responsible for altering a particular TFBS (Montgomery et al. 2007). This may result 
in a change in the binding affinity of the TF normally associated with this site and a 
subsequent change in the transcriptional activity of the gene. 
 
In silico analysis of the region of the CP promoter spanning the variants identified in this 
study demonstrated the presence of a number of putative TFBSs (Table 3.7). Only TFs that 
are responsible for the regulation of CP or that are biologically relevant to this study 
(involved in iron metabolism or liver-specific) will be discussed further. 
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One putative TFBS that was of particular interest in this study was the tumour suppressor 
protein 53 (p53) TFBS predicted to be abolished in the presence of the novel 5’UTR-
308G→A variant. The p53 gene encodes a protein that possesses sequence-specific DNA 
binding properties. It is thought that when cells are exposed to damaging agents, p53 is able 
to activate target genes involved in cell repair and apoptosis. This therefore prevents cells 
from replicating after damage or induces apoptosis of cells containing damaged DNA (Kastan 
et al. 1991, Zhan et al. 1993). The p53 TF therefore functions indirectly as a tumour 
suppressor. Mutations in the DNA binding domain of p53 are common in a variety of cancers 
and may prevent the activation of genes involved in DNA repair. This could enhance the 
genomic instability of tumour cells (Cho et al. 1994). It is feasible therefore to consider that 
variants in p53 TFBSs could result in decreased levels of gene expression of target genes and 
possibly result in subsequent tumour development. 
 
The novel 5’UTR-308G→A was found to be statistically associated (P=0.01) with OC in this 
study (Table 3.1). The fact that the binding motif for the p53 TF in patients with OC is 
abolished is indicative of the importance of this variant in the Black South African OC 
population screened in this study. However, this TFBS was only detected in one of the 
software programs utilised for in silico analysis (Table 3.7), and functional studies are 
therefore required to determine if p53 does interact with this region of the CP promoter. 
 
In a study by Fleming and Gitlin (1992), the entire promoter region of the rat (Rattus 
norvegicus) CP gene was characterised. An area of approximately 300 bp was determined to 
be critical for gene expression to occur and has been shown to be highly conserved in 
humans. The region from -393 to -348 bp upstream of the initiating ATG was found to exert a 
positive effect on gene expression and also showed sequence homology to the rat albumin D 
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site, known to bind to CCAAT/enhancer binding protein alpha (C/EBPα). In this study, the 
5’UTR-350C→T variant, which lies within the recognition site, was predicted to create a 
binding site for this TF (Table 3.7). CP levels have been shown to be up-regulated in 
response to certain aggressive cancers which may be mediated by C/EBP binding (Linder et 
al. 1981). 5’UTR-282A→G was predicted by two of the databases to abolish a C/EBPα 
binding domain (Table 3.7). C/EBP TFs are part of the bZIP family of TFs which have an 
important role in genes involved in the inflammatory response pathway. CP is an acute-phase 
protein that is involved in this inflammatory response pathway (Rice 1961). Therefore, 
disruption to C/EBPα binding domains may result in the down-regulation of CP expression 
leading to impaired inflammatory response.  
 
In addition to C/EBPα, many TFBSs for the GATA-binding protein (GATA) family of TFs 
were predicted for the CP promoter region (Table 3.7). The 5’UTR-567C→G variant was 
predicted by the in silico software programs to create a GATA1 and a GATA3 TFBS. The 
5’UTR-282A→G variant was also predicted to create GATA2 and GATA3 TFBSs. 
 
GATA1 has been shown to play a role in the regulation of genes involved in the haem 
biosynthesis pathway (Ferreira et al. 2005). GATA2 is involved in the control of 
haematopoietic progenitor cells (Tsai et al. 1994). The function of GATA 3 is less understood 
but it has been shown to play a role in erythroid development (Ferreira et al. 2005). Genes 
expressed in the liver, such as CP, are known to be regulated by the GATA TFs, although the 
exact role of these TFs in CP expression is unknown. It is therefore important not to 
disregard the effect that these TFs may exert on CP regulation. Additional research will aid in 
determining the role (if any) of the GATA TFs in CP expression. 
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Hepatocyte nuclear factors (HNFs) regulate genes that are expressed in the cells of the liver. 
Correct expression of these genes is determined by the binding of a wide variety of HNFs to 
the regulatory regions of these genes (reviewed by Costa et al. 2003). HNFs are members of 
the steroid/thyroid nuclear receptor family which are expressed predominately in the liver and 
acts as an essential regulator of liver metabolism and development. The 5’UTR-567C→G 
variant creates a putative HNF-1 site in the CP promoter (Table 3.7). Creation of this TFBS 
may result in increased expression of the CP gene. The 5’UTR-282A→G variant abolishes a 
putative HNF-1 motif (Table 3.7). The deletion of the T nucleotide at position -364 is 
predicted to abolish a HNF-3α and HNF-3β TFBS (Table 3.7). 
 
As previously mentioned, CP is an acute-phase protein that plays an important antioxidant 
role protecting cells against damage that may be caused by oxidative stress (Mukhopadhyay 
et al. 1998). It has been shown that members of the HNF family show an increase in 
expression in the presence of oxidative stress as a result of hepatitis C virus infection (Qadri 
et al. 2006). Excess iron catalyses the conversion of hydrogen peroxide to free radicals and 
leads to oxidative stress in various tissues (Andrews 1999). Disruptions to HNF TFBSs may 
perturb CP expression and therefore result in incorrect functioning of the antioxidant 
mechanism. It is possible that oxidative damage from the presence of excess iron could lead 
to cell damage and the subsequent formation of tumour cells. 
 
The presence of the 5’UTR-567C→G and the 5’UTR-563T→C variants are predicted to 
abolish a putative TFBS for YY1 (Table 3.7). YY1 is a zinc finger protein that has been 
shown to play a role in iron metabolism, particularly by interacting with transferrin (Adrian et 
al. 1996). It has also been implicated in gene silencing in the liver (Yan et al. 2001). CP is 
known to interact with transferrin during the transfer of iron molecules across the basolateral 
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membrane of the enterocyte. This TF could be involved in simultaneously mediating 
expression of these two proteins. 
 
A number of other putative TFBSs were predicted to be altered following in silico analysis of 
the variants identified in the CP promoter (Table 3.7). These include the binding motif for 
activator protein 1 (AP1) which has shown to be involved in cell proliferation, differentiation 
and tumourigenesis (Hilberg et al. 1993), upstream regulatory factor 1 (USF1) which has 
defined roles in regulation of genes expressed in the liver (Vallet et al. 1998) and spleen 
focus forming virus proviral integration oncogene 1 (SPI1) which plays a role in the 
development of myeloid and β-lymphoid cells which are important during an immune 
response (Tondravi et al. 1997). The functional importance of these TFs in regulation of CP 
expression should not be overlooked. 
 
A haplotype, consisting of six of the promoter variants detected in this study, was predicted 
to exist following analysis using the Haploview 4.0 program (Figure 3.19). The variants 
comprising the haplotype span a genomic region of 281 bp that was identified as a critical 
promoter region in R. norvegicus (Fleming and Gitlin 1992). This critical region is highly 
conserved in humans and is thought to be involved in gene expression. This haplotype was 
shown to be significantly associated with OC (P=0.01) in this study. TFBSs that are disrupted 
by the variant alleles of this haplotype have already been discussed and are summarised in 
Figure 3.20. It is interesting to note that three of these haplotype variants abolish SPI1 
TFBSs. SPI1 is known to play a role in regulation of genes involved in the inflammation 
response pathway (Tondravi et al. 1997). CP is an acute-phase protein which is up-regulated 
during times of cellular stress, and may therefore be controlled to a degree by this TF. 
Inadequate CP expression and an impaired immune response could potentially occur as a 
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result of disruptions to the binding motif for SPI1 caused by the variant alleles. However, no 
studies have demonstrated an involvement between CP and SPI1 to date. 
 
Figure 3.20 Schematic representation of the predicted CP promoter haplotype and the TFBSs 
that are abolished or created in the presence of the variant alleles. 
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Legend to Figure 3.20 
Schematic representation of the promoter haplotype predicted by Haploview 4.0. i) Gene annotation indicating 
the position of variants used as markers for haplotype assembly. Gene annotation is not drawn to scale and only 
indicates the positions of the variants. ii) Putative TFBSs that are created or abolished in the presence of the 
variant allele. -, TFBS abolished; +, TFBS created. Abbreviations: 5', 5 prime end; A, Adenine; AP-1, 
Activator protein 1; C, Cytosine; C/EBPα, CCAAT/enhancer binding protein alpha; c-myc, Myelocytomatosis 
viral oncogene c; G, Guanine; GATA1, GATA-binding protein 1; GATA2, GATA-binding protein 2; GATA3, 
GATA-binding protein 3; HNF-1, Hepatocyte nuclear factor 1; HNF-3α, Hepatocyte nuclear factor alpha; p53, 
Tumour suppressor protein 53; SPI1, spleen focus forming virus (SFFV) proviral integration oncogene 1; T, 
Thymine; TFBS, Transcription factor binding site; TFIID, Transcription factor IID; USF1, Upstream 
transcription factor 1; UTR, untranslated region; YY1, Ying Yang 1. 
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Coding region 
 
The exonic variants identified in this study were all subjected to in silico analysis using the 
ESEfinder program (Cartegni et al. 2003) (see Table 3.8). Exonic splicing enhancers (ESEs) 
are elements that function as binding sites for serine/arginine-rich (SR) proteins in a cis-
acting manner. SR proteins are responsible for defining exon/intron boundries by recruiting 
spliceosomal components. They bind to the ESE through their RNA-binding domain and 
recruit other essential components via protein-protein interactions and by antagonizing the 
action of splicing silencers in the vicinity (Cartegni et al. 2003). These SR proteins are 
therefore essential in the regulation of alternative splicing and exon inclusion. 
 
Accurate splicing of pre-mRNAs requires multiple cis elements which include the splice sites 
and polypyrimidine tracts (Freyer et al. 1989, Zahler et al. 1992). ESEs have been identified 
in exons associated with regulated splicing adjacent to introns with weak intronic splicing 
signals (Watakabe et al. 1993). Disruption of these vital elements can result in exon skipping 
or the suppression of intron removal, leading to aberrant mRNA formation (Lejeune et al. 
2001). There have been several human genetic diseases associated with defects in the 
alternative splicing mechanism in genes (Cáceres and Kornblihtt 2002, Zhang et al. 2004). 
 
Only those variants that demonstrated statistical significance with OC as well as those that 
were detected exclusively in the OC patient cohort will be discussed further. 
 
A synonymous variant, G633, was detected after HEX-SSCP analysis of exon 11 of the CP 
gene. This variant was shown to be statistically significantly (P=0.0004) associated with OC 
in this study. Synonymous SNPs in the coding exons of genes are traditionally regarded as 
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silent mutations. This is due to the fact that they do not result in a change in amino acid and 
subsequently the structure of the protein is not altered in any way. They can however have an 
effect on alternative splicing by inactivating or creating a splice site, interfering with other 
elements critical to the splicing mechanism, or by activating a cryptic splice site (Cartegni et 
al. 2003). These factors can result in the mutant exon being skipped by the splicing 
mechanism and the subsequent production of an aberrant protein. 
 
The novel variant, G633, was the only exonic variant to demonstrate significant association 
with OC following statistical analysis (Table 3.2) in this study. Analysis of this variant using 
the ESEfinder program demonstrated that a SC35 binding motif is created. This could mean 
that improper splicing occurs in the presence of this variant. The results from a homology 
search of CP in different species showed that this glycine amino acid was conserved in all the 
species tested, except for the mouse (Mus musculus) where a tryptophan was indicated in this 
position. This could indicate a level of evolutionary conservation at this amino acid and 
changes at this position may therefore not be tolerated. 
 
The G633 variant was identified in 13 of the 88 OC patients. The serum ferritin levels of the 
patients displaying the G633 variant differed markedly from each other. Seven of the patients 
showed normal SF levels [one male: 177.6 µg/l (reference range: 20-300 µg/l); six females: 
100.6 µg/l, 141.3 µg/l, 169.24 µg/l, 124.3 µg/l, 171.8 µg/l and 97.5 µg/l (reference range: 20-
200 µg/l)], three patients had elevated SF levels (one male: 409.9 µg/l and two females: 229.6 
µg/l and 714.39 µg/l), one patient demonstrated iron deficiency (one female: 13.5 µg/l) and 
one patient had extremely elevated SF levels (one male: 2152 µg/l). It is important to note 
that at the time of OC diagnosis, the majority of patients may be suffering from malnutrition 
due to the location of the tumours in the upper region of the digestive tract and the 
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subsequent inability to ingest sufficient nutrients. As previously discussed, iron is absorbed 
predominately from the diet and the body iron levels of OC patients may be compromised as 
a result of insufficient iron uptake. The relationship between iron parameters, measured at 
this stage of the disease, and the effects of variations in the iron metabolising genes are 
therefore difficult to correlate. 
 
It is possible that the G633 variant could be acting in conjunction with other variants 
identified in the CP gene, or other genes in the iron metabolism pathway, to produce the 
differences in iron levels observed in each of the patients. These data, along with the fact that 
the G633 variant was not detected in the control individuals, could indicate that this variant is 
associated with OC in the Black South African population. Further studies using the minigene 
system are warranted in order to determine what effect this variant has on protein expression 
in patients presenting with OC (Baralle et al. 2003). 
 
Another synonymous variant, Y425 (RefSNP ID: rs34237139), was detected in exon 7 of the 
CP gene following HEX-SSCP analysis. It was identified in the heterozygous state in only 
one female OC patient who had moderately elevated SF levels [266.6 µg/l (reference range: 
20-200 µg/l)]. Interestingly, this patient was also heterozygous for a number of other variants 
identified in this study (5’UTR-563T→C, 5’UTR-354T→C, 5’UTR-282A→G and 
IVS7+9T→C). It is possible that the combination of the variants could be playing a role in 
the iron overload demonstrated by this patient. ESEfinder results showed that the Y425 
variant abolished a SRp40 binding motif, as well as creating a SC35 site (Table 3.8). It is 
therefore possible that this silent mutation could exert a negative effect on exon splicing, a 
hypothesis that should be researched further. The sequence alignment indicated that the 
tyrosine amino acid at position 425 is evolutionarily conserved amongst all the different 
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species utilised. Changes at this position may therefore not be tolerated. Statistical analysis 
did not show any significant results (P=0.328) (Table 3.2). These results could indicate that 
this amino acid is essential for protein function and that any type of disruption to ESE 
binding motifs may result in incorrect gene product function, and therefore lead to the iron 
overload phenotype observed in this patient.  
 
A previously described intronic variant, IVS7+9T→C (RefSNP ID: rs35272481), was 
identified in the same patient as the Y425 variant. Two other previously identified (IVS4-
14C→T and IVS15-12T→C) intronic variants were also detected in the non-coding region of 
the CP gene following HEX-SSCP analysis. 
 
All genes are flanked by regions of non-coding DNA that were once considered to be genetic 
waste and subsequently termed “junk DNA”. However, these intronic regions between exons 
are now considered to have an important role in transcriptional regulation. Wang et al. (2006) 
have demonstrated the importance of the role of non-coding RNA molecules in a variety of 
cellular processes including the regulation of the production of ribosomal RNA (rRNA). 
These non-coding RNAs were shown to originate from non-coding DNA regions called 
intergenic spaces (IGS). SNPs in the introns of genes have the ability to interfere with intron-
exon splice sites, thereby creating variations in the splicing of certain genes. In eukaryotes, 
the accuracy of splicing is determined by the 5’ splice site, the 3’ splice site and the branch 
site (Cartegni et al. 2003). Variants that have an effect on the process of alternative splicing 
may not only be found in the regions of splice sites, but may also be found in regions that 
function as regulatory elements within exons or introns. Examples of these regions are termed 
enhancers or silencers (Pagani and Baralle 2004). 
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IVS7+9T→C was identified in a single patient with moderately elevated SF levels [one 
female: 266.6 µg/l (reference range: 20-200 µg/l)] in the heterozygous state. No significant 
(P=0.328) associations were observed following statistical analysis (Table 3.2) which 
indicates that this variant is possibly not involved in the development of iron overload or OC 
in the Black South African population. However, the patient with the IVS7+9T→C variant 
was also heterozygous for a number of other CP variants (5’UTR-563T→C, 5’UTR-
354T→C, 5’UTR-282A→G and Y425) identified in this study. This could infer that the 
interplay between the different variants and their effect on the regulation of gene expression 
could be responsible for the iron overload observed in this patient. IVS7+9T→C could 
potentially disrupt a splice donor site. However, it lies 3 bp beyond the published consensus 
sequence for 5’ (donor) splice sites (Padgett et al. 1986). Functional analysis of this variant 
using the minigene assay for intronic variants described by Cartegni et al. (2003) is necessary 
to determine if this variant is contributing to the disease phenotype. 
 
A novel missense mutation, V246A, was detected in exon 4 of the CP gene following HEX-
SSCP analysis. Non-synonymous SNPs in the coding regions of genes are called missense 
mutations and result in amino acid changes that subsequently lead to a protein that differs in 
its amino acid composition from that of the wild-type. Often this has no effect on the 
biological activity of the protein within the cell as many amino acid changes are tolerated. 
However, some amino acid substitutions, such as those at the active site of an enzyme, have a 
greater impact on the functionality of the protein. These changes can result in incorrect 
protein folding or protein-protein interactions that are compromised (de Pouplana et al. 
1998). 
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The novel V246A variant results in an amino acid change from valine to alanine at position 
246. As both of these amino acids are classified as non-polar hydrophobic residues, this 
variant is not expected to result in any structural changes within the protein. ESEfinder 
results showed that this variant is expected to create an SF2/ASF2 binding motif in the 
presence of the alanine amino acid, which may result in inaccurate exon splicing (Table 3.8). 
Protein homology comparison between species showed that the valine residue is conserved 
amongst the species. The macaque (Macaca mulatta) was the only one that demonstrated 
variation with an isoleucine in place of the valine. The V246A variant was detected only in 
the heterozygous state in two of the OC patients. Both individuals were female and had SF 
levels within the normal parameters [124.3 µg/l and 95.7 µg/l (reference range: 20-200 µg/l)]. 
No statistical significance (P=0.179) with OC was observed following χ2 analysis (Table 3.2).  
 
This evidence suggests that the novel V246A variant does not play a significant role in 
disease susceptibility. However, the fact that this variant is novel and that it was only 
detected in individuals presenting with OC, means that functional studies should be 
completed in order to conclusively exclude it from any association with OC in the Black 
South African population.  
 
Variants that could possibly result in the dysregulation of CP may lead to the formation of an 
aberrant protein that is unable to oxidise Fe2+ efficiently. This would lead to an increase in 
Fe2+, which is unable to bind to transferrin, in the serum. In addition, when CP levels are low 
or CP expression is inhibited, it is thought that a feedback mechanism may exist that prevents 
SLC40A1 from releasing Fe2+ from the cells. A resulting accumulation of iron within the 
intracellular compartment leads to oxidative damage of the cells. This damage is further 
exacerbated by the lack of CP, which in addition to acting as a ferroxidase enzyme, also 
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exhibits antioxidant properties. A study by Bosio et al. (2002) lends support to this 
hypothesis. In this study, a patient who was a compound heterozygote for two novel CP 
mutations demonstrated hepatic iron overload. An excess of iron has been previously 
described as a risk factor for the development of cancers, including OC. Variants detected in 
CP in patients presenting with OC should therefore be carefully considered with regard to 
disease pathogenesis. Further functional studies would provide vital information regarding 
the effect of these variants on gene expression.  
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OC is one of the most common forms of cancer found in the South African population, 
particularly in the Transkei region. Like the majority of cancers, it demonstrates an extremely 
complicated aetiology, with both genetic and environmental factors involved in disease 
development and progression. Previous studies have attempted to identify possible risk 
factors for OC as well as candidate genes involved in disease development. However, 
contributing factors leading to OC are still poorly understood on a molecular level and many 
genetic aberrations that could infer disease risk or resistance remain to be identified. OC is 
insidious in onset, as symptoms often present late in the development of the disease. As a 
result, conventional cancer treatment is highly ineffectual in the majority of cases, leading to 
the increase in mortality rate observed in OC patients. Early detection and screening 
programmes are therefore essential if this disease is to be effectively treated and managed in 
the future. An increase in iron has previously been identified as a potential risk factor in the 
development of many forms of cancer, including OC. This study therefore attempted to 
investigate any possible associations with iron dysregulation and OC in the Black South 
African population. 
 
The first objective of this study was to identify known and novel variants and/or 
polymorphisms within the CP gene, involved in the iron regulatory pathway, in patients with 
OC. This was achieved by PCR amplification of the regulatory, coding and flanking intronic 
regions of the CP gene, and subsequent analysis using HEX-SSCP analysis, RFLP analysis 
(where applicable) and semi-automated bidirectional DNA sequencing analysis. 
 
A total of fourteen previously described (5’UTR-567C→G, 5’UTR-563T→C, 5’UTR-
439C→T, 5’UTR-364delT, 5’UTR-354T→C, 5’UTR-350C→T, 5’UTR-282A→G, V223, 
Y425, R367C, D544E, IVS4-14C→T, IVS7+9T→C and IVS15-12T→C) and four novel 
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(5’UTR-308G→A, T83, V246A and G633) variants were identified, demonstrating that the 
first objective of this study was successfully achieved. 
 
The samples that were screened in this study comprised gDNA from 96 OC patients and 88 
population-matched, healthy control individuals. PCR amplification of the CP gene was 
successful in the majority of the samples. Restrictions on DNA quality and quantity however, 
meant that amplification optimisation for every sample was not successful for each fragment 
screened. This is reflected in the varying numbers of individuals (n) scored for each locus 
(see Tables 3.1 and 3.2). In addition, the PCR amplification of exon 13 was unsuccessful 
despite many attempts at optimisation. The primer set was redesigned using the Primer3 v0.2 
software however amplification of this fragment was still not achieved. This could possibly 
be due to the presence of polymorphisms within the primer binding sites that could inhibit the 
primer adhering correctly to the target DNA. Future research should aim to optimise the PCR 
technique of this exon, as possible variants related to OC may be present in this region. 
 
The size of the population screened in this study was sufficient to allow the detection of the 
aforementioned variants. In addition, allele and genotype frequencies of the variants detected 
were able to be calculated within the Black South African population. Screening of a larger 
patient cohort in the future could possibly allow for the detection of other previously 
described and novel variants not detected in this study. An increase in sample size may also 
aid in obtaining more statistically significant data. 
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The patient cohort demonstrated an equal distribution of males (n=48) and females (n=48). 
However, the population-matched control group was comprised of an unequal number of 
male and female individuals. This was unfortunate as it made it impossible to compare the 
prevalence of the variants identified between males and females with any accuracy. 
 
A marked variation in iron parameters within the patient and control groups meant that it was 
extremely difficult to draw any substantial conclusions about the effect of the individual 
variants on iron regulation. This was further complicated by the fact that the iron levels of 
OC patients may be severely compromised as a result of malnutrition. The diagnosis of OC 
frequently occurs at a late stage in disease development. At this point, the size and location of 
the tumours of many patients may have already impeded their ability to ingest sufficient 
dietary nutrients, including iron. It would be beneficial for future studies to obtain the iron 
parameters of OC patients before severe malnutrition becomes a factor. However, this is a 
challenging task due to the complexity of OC symptoms and the subsequent delay in disease 
diagnosis. 
 
HEX-SSCP analysis, RFLP analysis and semi-automated bidirectional DNA sequencing 
analysis were the detection methods employed in this study. With respect to the first 
objective of this study, to detect known and/or novel polymorphisms in the CP gene, these 
methods proved to be effective. However, previously described polymorphisms in this gene 
were not detected in this study. This occurrence could be due to a variety of factors, including 
the fact that these polymorphisms may not be present in the Black South African population, 
these variants do not contribute to OC susceptibility and are therefore not generally present in 
the OC population or the detection method of choice was not sensitive enough to identify 
these variants. 
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The lack of detection sensitivity was demonstrated during the screening of exon 2. In order to 
distinguish clearly between homozygous and heterozygous individuals for the T83 variant, 
RFLP analysis had to be employed. It is therefore possible that the HEX-SSCP technique was 
not sensitive enough to detect other variants that may be present in the CP gene in the patient 
and control cohorts used in this study. 
The combination of single-strand conformation (SSCP) analysis with heteroduplex (HEX) 
methodology, as utilised in this study, offers the advantages of being inexpensive and 
relatively simple to use. It demonstrates 70-95% mutation detection sensitivity when DNA 
fragments smaller than 150-250 bp in size are analysed (Xiao and Oefner 1992, Hayashi and 
Yandell 1993), but is unable to detect large genomic rearrangements (Fujita and Silver 1994). 
It is however preferable to SSCP analysis alone, which is expected to demonstrate only 70% 
specificity in detecting single base pair changes (Sheffield 1993). The majority of the 
fragments analysed in this study were greater than 250 bp which could account for some 
previously described CP variants being undetected in this study. Sensitivity of this method is 
further influenced by the position of the variant within the screened fragment, pH, 
temperature and gel composition.  
 
Further optimisation of this technique could contribute to future work involving the screening 
of a larger population. In addition, other detection techniques that demonstrate increased 
sensitivity could be employed. Denaturing high performance liquid chromatography 
(dHPLC) is currently considered to be superior to SSCP analysis as it demonstrates high SNP 
detection sensitivity (92-100%) and larger fragments (198-732 bp) are also able to be 
effectively analysed (Underhill et al. 1997). To date, the most accurate mutation detection 
method is considered to be semi-automated DNA sequencing which has the ability to detect 
all variants present within a DNA sequence (Kristensen et al. 2001). However, this technique 
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is relatively expensive and is therefore not considered to be effective for the initial screening 
of a population. 
 
The second objective of this study was to determine if any significant association exists 
between the variants identified and OC. This was achieved using various statistical methods. 
The patient and control cohorts were tested for HWE at the variant loci. All groups were 
found to conform to HWE in this study (Tables 3.4 and 3.5). HWE is imperative for the 
accurate determination of the significance of the findings of the study. 
 
Genotype and allele frequencies of the variants were determined by allele counting and were 
subsequently compared between the OC patients and the population-matched controls to 
determine any significant association with OC. Statistically significant association was 
observed for the novel 5’UTR-308G→A (P = 0.012) and G633 (P = 0.0004) variants 
identified in the CP promoter and coding region respectively. It is therefore possible that the 
presence of these variants may contribute to OC susceptibility. Further studies are required to 
elucidate the role of these potential disease-contributing mutations.  
 
The third objective of this study involved the bioinformatic analysis of variants identified in 
this study using the appropriate in silico programs. In silico analysis of the region of the 
promoter spanning the identified variants sought to identify putative TFBSs that could 
possibly regulate the expression of CP. The programs employed for this analysis used 
different algorithms and criteria to establish if a TFBS is abolished or created in the presence 
of the variant allele. 
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Several TFBSs were found to be altered by the variants in the CP promoter region which 
could indicate changes in gene expression in patients with OC. In silico analysis using these 
particular programs is a predictive method only and provides a cost-free method of analysing 
regulatory regions. In no way does it serve to specify the presence of in vivo TFBSs 
absolutely. It is however an informative tool in the process of developing future functional 
studies to elucidate the function of identified variants. 
 
With regard to future studies, transfection experiments using luciferase reporter constructs 
should be conducted for the promoter variants identified in this study. Particular attention 
should be paid to the variants in the 281 bp genomic region that constitutes the significant 
haplotype identified in this study (Figure 3.20). Luciferase experiments should be carried out 
to determine if this region is functionally important in driving CP expression by cloning 
normal promoters and those lacking the 281 bp region into suitable vectors and observing any 
difference in transcriptional activity. This information could enhance our understanding of 
the role that this gene plays in iron regulation in the Black South African population and may 
aid in establishing the in vivo functionality of these variants. 
 
Bioinformatic analysis of the variants identified in the CP coding regions was conducted 
using the ESEfinder program. All of the novel variants identified in the exonic regions (T83, 
V246A and G633) as well as the previously described exonic variants (V233, R367C, Y425 
and D544E) were predicted to affect splicing by altering the binding sites for various SR 
proteins. Therefore, the role of these variants in the development of OC should not be 
disregarded. However, this program does not present conclusive evidence for the functional 
impact that these variants may have on splicing. Functional studies should therefore be 
 
 
109
                                                                         CONCLUSIONS AND FUTURE PROSPECTS 
performed in future to determine what role, if any, these variants play in exon splicing in the 
CP gene. 
 
In order to further investigate the potential role that the regulation of iron homeostasis plays 
in the development of OC, other genes involved in this pathway should be studied. The 
coding regions of HFE, HMOX1, SLC40A1, HAMP, CYBRD1 and HJV have already been 
screened for novel and/or previously described polymorphisms in the existing population 
(Human 2007). Analysis of the promoter regions of these genes is currently being performed 
in our laboratory. All of these data combined could contribute significantly to our knowledge 
of how iron overload acts as a risk factor for OC, and may serve to identify possible modifier 
genes for this complex disease. Future research should also be extended to include the White 
and Coloured populations. Data accumulated from these genetically distinct South African 
population groups will no doubt further our understanding of iron dysregulation and OC 
pathophysiology. 
 
It is also important that future researchers aim to collect as much clinical information on the 
patients and controls as possible (ie: smoking status, alcohol consumption, nutrition and 
workplace) to enable more in-depth analysis of the effects of the variants on OC aetiology. It 
will also be imperative in the future to compare iron parameters (serum ferritin and 
transferrin saturation) between patients and control individuals to try and elucidate the effect 
(if any) that these variants have on iron regulation. 
 
Novel and previously described variants in the Black South African OC population were 
successfully identified in this study. Statistically significant associations between two of the 
novel variants were observed with OC. Although no other statistically significant associations 
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were observed with any of the other variants identified in this study, the role that they may 
play in the aetiology of OC should not be disregarded. The effect of various combinations of 
variants in CP, and other regulatory genes, could potentially be a factor in disease 
development. Future research may enhance our knowledge of how these variants contribute 
to OC pathogenesis as well as providing a greater understanding of how dysregulation of the 
iron metabolism pathway can act as a risk factor for this disease. This study constitutes an 
integral part of a much larger long-term analysis of the correlation between aberrations in 
iron regulatory genes and disease. The data generated from this study, in conjunction with 
that of the larger study, may potentially lead to the identification of molecular markers for 
OC. These markers could ultimately serve as an effective tool in the pre-symptomatic 
diagnosis and subsequent treatment of this disease. 
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5.2 ELECTRONIC DATABASE INFORMATION 
 
BLAST: http://www.ncbi.nlm.nih.gov/blast 
 
Ensembl: http://www.ensembl.org 
 
ESEfinder: http://exon.cshl.edu/ESE 
 
GenAtlas: http://www.genatlas.org 
 
HapMap: http://www.hapmap.org 
 
JASPAR CORE: http://www.jaspar.genereg.net 
 
PATCH: http://www.gene-regulation.com/cgi-bin/pub/programs/patch/bin/patch.cgi  
 
Primer3: http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi,2002  
 
TRANSFAC ®7 database: http://www.gene-regulation.com/pub/databases.html#transfac 
 
STATISTICA [StatSoft, Inc (2003) STAT (data analysis software system)], version 6 
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APPENDIX 1: LIST OF CHEMICALS/REAGENTS USED IN THIS 
STUDY AND THEIR SUPPLIERS 
CHEMICAL/REAGENT SUPPLIER 
AA Sigma-Aldrich 
Agarose  Laboratory Specialist Services 
APS Merck 
BAA Sigma-Aldrich 
C13H28N2Na4O13S Fluka 
C19H10Br4O5S Merck 
Cresol Red Merck 
ddH2O Adcock-Ingram 
dNTPs (dATP, dTTP, dCTP, dGTP) Fermentas 
EDTA Merck 
EtBr Merck 
EtOH Merck 
H3BO3 Kimix 
H2NCHO Sigma-Aldrich 
MgCl2 Bioline 
NaCl Fluka 
(NH2)2CO Sigma-Aldrich 
SfcI New England Biolabs 
Sucrose Associated Chemical Enterprises 
Taq polymerase Bioline 
TEMED Fluka 
Tris-HCl Fluka 
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APPENDIX 2: PROMOTER AND CODING REGIONS OF THE CP 
GENE INDICATING PRIMER BINDING POSITIONS AND VARIANTS 
IDENTIFIED IN THIS STUDY 
 
The promoter (5’ to 3’) and coding regions (5’ to 3’) of the CP gene were acquired from 
Ensembl and GenAtlas (reference numbers indicated). The primers designed for the 
amplification of the promoter region are highlighted in various colours which are described in 
the key. Primers designed for the amplification of the coding regions are indicated using 
various text colours. Red text indicates the forward primer of the first primer set of a 
particular fragment and blue text indicates the reverse primer. In cases where a particular 
fragment has been split in two for amplification purposes (see Table 2.4), green text indicates 
the forward primer of the second primer set and purple denotes the reverse, with the first 
primer pair the same as described above. Arrows flank the primers with arrowheads 
indicating the orientation of each primer. The translation initiation site (ATG) and the stop 
codon (TGA) are indicated in bold red text. The variations that were detected in the current 
study are in bold text, highlighted in grey and the superscript number indicates the nucleotide 
position (described in the key). The 5’UTR and the introns are indicated in lowercase text 
while the mRNA encoding regions (transcribed regions) are indicated in uppercase. 
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CP promoter sequence 
[ENSG00000047457 (Ensembl)] 
 
aagactaatctttgcctctgaagacaggtttagttatggtttgtttatttgatgattaaaacaaagttattagcc
cctgttaggctctgctagttatttgcatatagcaatacagaatgatctggtaaagtttttatgcagatttggtcc
aagctcataaaacagataaattcttccaaattaaattcttatttttgtttacttaaatttggcatgctagatatc
atgtttcatatcataaagctgcaattaatcatttgttagacttttagaaatagtcatgcaccacataataatgtt
tgagtaaatgacaaactgcatatgtgatggtggtcccataagattataataacatatttttactgtacattttct
atgtttgcatatgtatagatacagaaatatcattgtgttacaattgtctatagcattcagcatagttatagactg
tacaggtttgtagcctaggagcaataggtatacc1atat2agcctacctagatgtatagtaggctatatcatata
agtctgtgtaagtacactctgtgatagtcacacaatgacaaaatagcctaacaatgcatttctcagaacgtatcc
ctgtcattaagaac3gactgtagtaaaaagctacatgttttgattcattttacataattcttatcctgatttact
aaaagtgcactgttt4gcaggacact5gtgc6tgtgacatattgtcagaggaacaaagggagcatttagacacg7t
tctctgccctcctggaatttacaca8atgaatggaaaaaggcacagagttatgcacaccctaatgcctccaacaa
taactgttgactttttattttcagtcagagaagcctggcaaccaagaactgtttttttggtggtttacgagaact
taactgaattggaaaatatttgctttaatgaaacaatttactcttgtgcaacactaaattgtgtcaatcaagcaa
ataaggaaagtcttatttataaaattgcctgctcctgattttacttcatttcttctcaggctccaagaaggggaa
aaaaatgaagattttgatacttggtatttttctgtttttatgtagtaccccagcctgggcgaaagaaaagcatta
ttacattggaattattgaaacgacttgggattATGAAGATTTTGATACTTGGTATTTTTCTGTTTTTA
TGTAGTACCCCAGCCTGGGCGAAAGAAAAGCATTATTACATTGGAATTATTGAAACGACTTG
GGATTATGCCTCTGACCATGGGGAAAAGAAACTTATTTCTGTTGACACgtaagtcactattt
ttattgtttatagaccaa 
 
 
CP promoter region key:  
Primers  Variant 
Amplicon 1 CPP1F & R  1 5’UTR-567C→G 
Amplicon 2 CPP2F & R  2 5’UTR-563T→C 
Amplicon 3 CPP3F  3 5’UTR-439C→T 
Amplicon 4 CPP4F  4 5’UTR-364delT 
Amplicon 5 CPP5R  5 5’UTR-354T→C 
Amplicon 6 CPP6R  6 5’UTR-350C→T 
Amplicon 3 & 5 CPP3R & CPP5F  7 5’UTR-308G→A 
Amplicon 4 & 6 CPP4R & CPP6F  8 5’UTR-282A→G 
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CP coding regions 
[NM_000096 (GenBank)] 
 
Exon 1 
ttttttggtggtttacgagaacttaactgaattggaaaatatttgctttaatgaaacaatttactcttgtgcaac
actaaattgtgtcaatcaagcaaataaggaagaaagtcttatttataaaattgcctgctcctgattttacttcat
ttcttctcaggctccaagaaggggaaaaaaATGAAGATTTTGATACTTGGTATTTTTCTGTTTTTATGTAGTACC
CCAGCCTGGGCGAAAGAAAAGCATTATTACATTGGAATTATTGAAACGACTTGGGATTATGCCTCTGACCATGGG
GAAAAGAAACTTATTTCTGTTGACACgtaagtcactatttttattgtttatagaccaaaattttaagttattttt
aaaggatagagccaataagatgaaatatttttaaaatttcttatatacagaaactgcaaaatgtgggcttgaaac
ccaagacacttgaatcaatctcctttatattcctgtatattttttatttggtggac 
Exon 2 
taaaataacagggctaactaccagccctccacttcaattttggaggcatccctacaacaggcaaacattcaatgt
gatgtgctcattaatttctctaattataatgttattaaattataatgataatgtcatccctagaaatgatggctt
ctgatagagttgtcttgtttttctttgcagGGAACATTCCAATATCTATCTTCAAAATGGCCCAGATAGAATTGG
GAGACTATATAAGAAGGCCCTTTATCTTCAGTACACAGATGAAACCTTTAGGACAACT1ATAGAAAAACCGGTCT
GGCTTGGGTTTTTAGGCCCTATTATCAAAGCTGAAACTGGAGATAAAGTTTATGTACACTTAAAAAACCTTGCCT
CTAGGCCCTACACCTTTCATTCACATGGAATAACTTACTATAAGGAACATGAGGgtaagttcagctcatgtagct
ggaatttcctcttacttttcagtagaagtgccttttagcttctaaaattgtggacttctctcctggataagacat
ataactgccattcagctcttaactattttttttttatttttttttaattttttttgacttctgtcacccaggctg
gagtgcagt 
Exon 3 
cttctacacaccctagccattagcctttcattttcctgtgtccaaataggataacacatccccaaggatcacata
gtagatgtttaataaatgtttgctgaatgaattaatggactatctattctctcatttaagttcaaacacattcac
tttgcaccttcattgcatgttgcttcctagGGGCCATCTACCCTGATAACACCACAGATTTTCAAAGAGCAGATG
ACAAAGTATATCCAGGAGAGCAGTATACATACATGTTGCTTGCCACTGAAGAACAAAGTCCTGGGGAAGGAGATG
GCAATTGTGTGACTAGGATTTACCATTCCCACATTGATGCTCCAAAAGATATTGCCTCAGGACTCATCGGACCTT
TAATAATCTGTAAAAAAGgtacatcttctccttattgcacatgctatatgaccaaaagacaggggcagggcagtt
tgtcttttaaaaagaaatcaagtcttctgtgctgagattgagcaggtaaggtagagaggtggtaagtagaaaaaa
aggaagggaagagccaggcaggactaggagaagaagggataaatagaa 
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Exon 4 
tactgatcataaaaattccctgagtgtttctgtctgtaaaacaggagtgactggtccagacttgtgatttattcg
aaaaaataaatactaacatttttaaaaactataaatcacctgaaaacataaatcaaaatacatgctaaaagttta
gtcttgctaaaatagtaactttaactccagATTCTCTAGATAAAGAAAAAGAAAAACATATTGACCGAGAATTTG
TGGTGATGTTTTCTGTG2GTGGATGAAAATTTCAGCTGGTACCTAGAAGACAACATTAAAACCTACTGCTCAGAA
CCAGAGAAAGT3TGACAAAGACAACGAAGACTTCCAGGAGAGTAACAGAATGTATTgtaagattacagcagacat
gttaactttacttttttttcccttgatccattaattctgctaagcttattccctcacataaataagtactgtgtg
tctagtctgtggtccttataacaaagcatattggatgtgcaatttgatattcagctaagtaagtcagaataaaaa
ctctaagccag 
Exon 5 
ttccaaaatgaaagagtgctgtgattgattagcaatgtctgacatgagtatagggggcaagaataccagcatgtg
tgccagatatttgccattccaaattgattctatttatatagaggtaactctcactatctcaagcattaatgactc
ttagtcacaaactctgc4tcttgacttacagCTGTGAATGGATACACTTTTGGAAGTCTCCCAGGACTCTCCATG
TGTGCTGAAGACAGAGTAAAATGGTACCTTTTTGGTATGGGTAATGAAGTTGATGTGCACGCAGCTTTCTTTCAC
GGGCAAGCACTGACTAACAAGAACTACCGTATTGACACAATCAACCTCTTTCCTGCTACCCTGTTTGATGCTTAT
ATGGTGGCCCAGAACCCTGGAGAATGGATGCTCAGCTGTCAGAATCTAAACCATCTGAAAGgtaggacatcttta
cctgaaattagcagtcagctgaaaaaggtggttactgggaatcagaatctaaaagctaaatatctttgaaataat
ctgagctttgaactggcatcttagttttatccctatgatggtatatataataatgtaataaaaaaagactgtaag
acaggaatattataaa 
Exon 6 
ttttaaacttgagttttccatcattaatttatttacagctgtctgccctagtttatagtactgttgctatctgtc
tattccttcaatttctacttgtcatcacccgagcagtgtttacagggcaataggagagagaaacattgtcttcat
taatcaatgcctctttctgtttcatttcagCCGGTTTGCAAGCCTTTTTCCAGGTCCAGGAGTGTAACAAGTCTT
CATCAAAGGATAATATCC5GTGGGAAGCATGTTAGACACTACTACATTGCCGCTGAGGAAATCATCTGGAACTAT
GCTCCCTCTGGTATAGACATCTTCACTAAAGAAAACTTAACAGCACCTGGAAGgtaatttacaaaaaaagagtac
tatttcaaaatatgctctcccccgcacaaaggaactacaaaaggctaattcagcaattaaaattttaattggtat
ctgaaattgagtaactagactgctaaatatttattaaggtatttgatgtaagagtctgagcttgagaactatgag
ttttgagt 
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Exon 7 
ctatgagtggactggaactgtctgctttgtttgagtaactggtacggattgctataaatcatggataatattcat
ctctaagcactggtcagaatttttctcttcaattagcaccttaagtgaatacctgctttctgttctacttcaacc
ccagcattaaacacttttttccccctgcagTGACTCAGCGGTGTTTTTTGAACAAGGTACCACAAGAATTGGAGG
CTCTTATAAAAAGCTGGTTTAT6CGTGAGTACACAGATGCCTCCTTCACAAATCGAAAGGAGAGAGGCCCTGAAG
AAGAGCATCTTGGCATCCTGGgtgagttct7tgcagaatatatatggctggtttactcttcccatgggctacatc
aacctcagaaagaatagtaacttcaggacctactgcatgatttctatgtgttaagtaggcgtgtggaagataaaa
caataaaatgcagcagctaagtacttttccaaatgtaaattaccaatggtaa 
 
Exon 8 
ccaacctcgacatatcagattgattatggacttctcaaaaaccaagctttccattcaccacaaataagcgtgttg
ctcctagtagttcttgccagagaacacagtcaaagaagataactatcttatacattctgcatgttacataccaag
gaaggataataattctctctttgttcccagGTCCTGTCATTTGGGCAGAGGTGGGAGACACCATCAGAGTAACCT
TCCATAACAAAGGAGCATATCCCCTCAGTATTGAGCCGATTGGGGTGAGATTCAATAAGAACAACGAGGGCACAT
ACTATTCCCCAAATTACAACCCCCAGAGCAGAAgtgagtatacagcactgtgtaacaaatcaacaatgtttaata
acccactgtactggtcactgacagtatgctgcaaaaactgaaggcaggaactcccaaggaaaccgctcatatatc
atttctaggcatcatgccaggaaacaaataaaccccttctcctacctccaattggtttacgga 
Exon 9 
ctatctggatgcaatcacatcggtctgttatctgacaccagagcataagtgggattccattctaatttataacaa
agaactcagaagtgggctattctagactaaacttagtctactttgtggctcaaatgaccacgttagaaagcacac
ttcacctctctaatgtgacctttctcacagGTGTGCCTCCTTCAGCCTCCCATGTGGCACCCACAGAAACATTCA
CCTATGAATGGACTGTCCCCAAAGAAGTAGGACCCACTAATGCAGATCCTGTGTGTCTAGCTAAGATGTATTATT
CTGCTGTGGAT8CCCACTAAAGATATATTCACTGGGCTTATTGGGCCAATGAAAATATGCAAGAAAGGAAGTTTA
CATGCAAATGGGAGACAGgtaagtccaactggggaaaaaaaaattgttcaatctctttgaaaatgatcatttgac
agaaatagaaatatctaacctcatcattatctccaaaaatactttagtatatacctttaaaagataaggacttct
ttaaaaatgcccacaattatcacaccttaaaataataataacacacat 
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Exon 10 
taccaaagaaagctctggtggtgaactgaaatatttcaggaaccctagtttacaaagagcaacagaaacttctgt
tctcattctttcctttaggtgtgtttgtgcataaatagtattgtgcacatggaagtcttctgctttattcattct
gtctccatctcattttgttttgatttacagAAAGATGTAGACAAGGAATTCTATTTGTTTCCTACAGTATTTGAT
GAGAATGAGAGTTTACTCCTGGAAGATAATATTAGAATGTTTACAACTGCACCTGATCAGGTGGATAAGGAAGAT
GAAGACTTTCAGGAATCTAATAAAATGCACTgtaagtactgcatcatccaccaatctaccaagttattttagtac
tgcatatgtaatgcttttaactaaacaaaatgtgaagagctttgctcattgattattttttcaataaacgattac
aatagtgtcctgaaggtaatctcactggttatttgatgtgtctgtcagttatccattattt 
Exon 11 
tgctctgaaatgccaggaaccacaaggagttgcaaggatactcctgacacataaagcgtgggcaagcctgaatag
gtcttttaaaaattaaaaaaacaaagttggtcctggaaagtctgtgaggttgtcatgtagtagaatctaaaccac
ttccaaaatgttatttcccaacttttacagCCATGAATGGATTCATGTATGGGAATCAGCCGGGT9CTCACTATG
TGCAAAGGAGATTCGGTCGTGTGGTACTTATTCAGCGCCGGAAATGAGGCCGATGTACATGGAATATACTTTTCA
GGAAACACATATCTGTGGAGAGGAGAACGGAGAGACACAGCAAACCTCTTCCCTCAAACAAGTCTTACGCTCCAC
ATGTGGCCTGACACAGAGGgtatatttacttaaagccaagtctctattggatggatttgtgtagttttggtttaa
aatcctgtagcagaatgtgttgggtgataaacttatcccttccccaagcctctgaagtgcccttcctatctttga
aagagcaagtctaggccactatcagctgaagtatgtaccagataggtct 
Exon 12 
gcacacacttgatctgctctaagaacagcaaaaggatggatggagcagggtgagcagaaggtgtggaaagctaga
tcacctgaggccatgataaggacttcagcattaattctgaggaaggtggagagccccagagggcactagcaaaga
agtgacatgttttcttatttaccactccagGGACTTTTAATGTTGAATGCCTTACAACTGATCATTACACAGGCG
GCATGAAGCAAAAATATACTGTGAACCAATGCAGGCGGCAGTCTGAGGATTCCACCTTCTACCTGGGAGAGAGGA
CATACTATATCGCAGCAGTGGAGGTGGAATGGGATTATTCCCCACAAAGGGAGTGGGAAAAGGAGCTGCATCATT
TACAAGAGCAGAAgtaattctccagactctgattcccaatttcagcagtaattttaggtttccttttcagagaag
taagaattacaccaaattttagaaaaaaaaaaaagttgcattaaacaataacaacaacaacaacaacaacaacaa
aacacttcctaggaacttgtccttattcatttccgcttctctc 
Exon 13 
ttctaccacacagacttttaaagtcttattatgcattcctacttggatagaagagtgatgatttaaaactactat
aattactctaataaaaactatatttttattcaaaatttaaagtttaaaacttaagttacattttcattaagacaa
atactaaccttagttgtttttttttttaagTGTTTCAAATGCATTTTTAGATAAGGGAGAGTTTTACATAGGCTC
AAAGTACAAGAAAGTTGTGTATCGGCAGTATACTGATAGCACATTCCGTGTTCCAGTGGAGAGAAAAGCTGAAGA
AGAACATCTGGGAATTCTAGgtatgttaatatctccagtttatcaggtgtgggttaatgatgtgatgctacctgc
agtaaccgtcaattcatgtctatgggtttcattttcttggttcatatatcaaagttgttcaaataaaaatttaaa
aattagttatctaatgaaataagactgatgtttattaaataatatgacat 
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Exon 14 
aaatggtctccatttttatttccagtgtattgattccaaattccctgggacgcagtataaatccaagagtattat
accacaaacccatgggggagagaaacaagttatctttgctgatctttgcttttattactaagttagaccttctga
ttggacactcttcctcttcacttttgccagGTCCACAACTTCATGCAGATGTTGGAGACAAAGTCAAAATTATCT
TTAAAAACATGGCCACAAGGCCCTACTCAATACATGCCCATGGGGTACAAACAGAGAGTTCTACAGTTACTCCAA
CATTACCAGgtactcacgggggcgggggtgggggtggtgcattttaacaggctgtacagcctttccacagattac
tctcatcatagagagtctggaccaagaaagtgaaaagggaggtagttgtgaagaggggatgcaaggaggtgtctg
tgtgtatgcaagtacatgcacatgcttgtactaaaaaaa 
Exon 15 
aaactaaattcctgaaaacaatcttgagtaccacaatttttaaaaactaattacactgacatttccagttcctgg
gtcctagttatcaaggctgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtgtacaatataaaccaaataca
accagatccattaacacttgatgaatttagGTGAAACTCTCACTTACGTATGGAAAATCCCAGAAAGATCTGGAG
CTGGAACAGAGGATTCTGCTTGTATTCCATGGGCTTATTATTCAACTGTGGATCAAGTTAAGgtaaaatacaaat
catttgttttgtgacacttcccaaaatagacacacaattgaaggaagacaaggttagtgttttcctgtggtccaa
ttctacgttaaaatcctaggaaaataaactgtttgcaatctactttagcaactatgctgctacctatgacacaca
agacaaaaatctaacat 
Exon 16 
ccattgttccaatttaactacttcaagtgaaaagttactaaattggcagtaccacattgggcaaagtctgttact
tcaattggtctctccaaaattcctgaggccctgggtgcaaagtctcagttctctgaaatcctgacctaattcaca
agggttactgaagattttt10cttgtttccagGACCTCTACAGTGGATTAATTGGCCCCCTGATTGTTTGTCGAA
GACCTTACTTGAAAGTATTCAATCCCAGAAGGAAACTGGAATTTGCCCTTCTGTTTCTAGTTTTTGATGAGAATG
AATCTTGGTACTTAGATGACAACATCAAAACATACTCTGATCACCCCGAGAAAGTAAACAAAGATGATGAGGAAT
TCATAGAAAGCAATAAAATGCATGgtatgtcacattattctaaaacaatttttctacttttttatcattttctct
ttcaaataaaattattttggagaccattcatttgttttgtcttaaaataaaccacttctgcctcactttgtatgt
caggtagaatcctgttcaaaacaaaaaggggactatgttcaaaatcatttgcta 
Exon 17 
gcctagaaaagcaatgtgatattattgactttaaagtatccatttctctcatttgtagtaaaataagtcctatta
catcaaaaagattctttacattaacctaataatcatattttctttgaaatagctattggtttaaaatatcctgaa
aagtaacataaaaccatatgctttccctagCTATTAATGGAAGAATGTTTGGAAACCTACAAGGCCTCACAATGC
ACGTGGGAGATGAAGTCAACTGGTATCTGATGGGAATGGGCAATGAAATAGACTTACACACTGTACATTTTCACG
GCCATAGCTTCCAATACAAGgtaagagctatccatggcaattactcttgctctgtttgaaaatgttttaatacaa
gtgaagaaaatattttctcagagagacttatgaaaaaaagctgcaaagagtacagccggtgcttcatatccgtgg
attccccacccaggattcaatcatggattgaaaatattcaggaaaaaata 
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Exon 18 
aagacttattaggaatacaaaaaccacattttaccatttgtattaaacacagaaacgagctcgattttttaaaaa
cagatttatccattttttcaatatccctgagctgaacattaacaaatgacatgagtgaactctcatatacaatat
tatacattatttgtcatttttctaattaagCACAGGGGAGTTTATAGTTCTGATGTCTTTGACATTTTCCCTGGA
ACATACCAAACCCTAGAAATGTTTCCAAGAACACCTGGAATTTGGTTACTCCACTGCCATGTGACCGACCACATT
CATGCTGGAATGGAAACCACTTACACCGTTCTACAAAATGAAGgtgaatatccaggtagtaattctagaagccat
atataaaagatataactaaaggaactactttgcctaaatacttcccccaatatgatgcatcaatatgaagcattt
gtgaatctgctgccctgatttcttccttctctacctccaaacaggatttttttcctgctaaatggtgagggat 
Exon 19 
atctttctttaaataaagcagcaatagaatgagagatttttaaacatataaaaagcagaaaaatataaatgaatc
aggagtaaagtaacattaaaaattggaatacatttaaagaaccatctactaatttctaaccatatattattttta
ataatggtcttaaaatttctttttctatagACACCAAATCTGGCTGAATGAAATAAATTGGTGATAAGTGGAAAA
AAGAGAAAAACCAATGATTCATAACAATGTATGTGAAAGTGTAAAATAGAATGTTACTTTGGAATGACTATAAAC
ATTAAAAGAAGACTGGAAGCATacaactttgtacatttgtgggggaaaactattaattttttgcaaatggaaaga
tcaacagactatataatgatacatgactgacacttgtacactaggtaataaaactgattcatacagtctaatgat
atcaccgctgttagggttttataaaactgcatttaaaaaaagatctatgacc 
 
  
CP coding region key:  
Primers  Variant 
Forward Primer 1 Reverse Primer 1  1 T83 
Forward Primer 2 Reverse Primer 2  2 V223 
   3 V246A 
   4 IVS4-14C→T 
   5 R367C 
   6 Y425 
   7 IVS7+9T→C 
   8 D544E 
   9 G633 
   10 IVS15-12T→C 
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